

PATENT SPECIFICATION

(11) 1 508 391

1 508 391

- (21) Application No. 1595/76 (22) Filed 15 Jan. 1976
 (31) Convention Application No. 542 553
 (32) Filed 20 Jan. 1975
 (31) Convention Application No. 641 511
 (32) Filed 17 Dec. 1975 in
 (33) United States of America (US)
 (44) Complete Specification published 26 April 1978
 (51) INT CL² C07C 87/02; A61K 31/13, 31/395; C07C 91/00, 131/00;
 C07D 211/14, 295/04
 (52) Index at acceptance

C2C 1341 1342 1492 1530 1532 1562 1582 1626 1731 200 211
 215 21X 220 221 225 226 227 22Y 246 250 251 252
 253 255 256 25Y 282 28X 29X 29Y 304 305 30Y 311
 313 314 316 31Y 321 322 323 32Y 338 339 342 346
 34Y 351 355 35X 360 362 364 365 366 36Y 373 37Y
 386 387 388 396 397 401 409 40Y 43X 440 455 45Y
 464 509 50Y 583 593 613 620 623 624 625 628 62X
 630 635 650 652 658 662 665 675 694 697 699 69Y
 701 709 719 776 778 77X 77Y 790 79Y KS LJ LL MV
 NL NM QN UJ UL UR WH ZK ZL ZM




(54) PHENYALKYLAMINES

(71) We, STERLING DRUG INC., a Corporation organised under the laws of the State of Delaware, United States of America, of 90 Park Avenue, New York, State of New York, United States of America, do hereby declare the invention, for which we pray that a patent may be granted to us, and the method by which it is to be performed, to be particularly described in and by the following statement:—


This invention relates to phenyl-lower-alkylamines useful as anti-inflammatory agents.

A very large class of organic compounds of widely diverse structural types are known to be useful as anti-inflammatory agents, but many of such anti-inflammatory agents are acidic, for example α -(3-benzoylphenyl)propionic acid, known generically as ketoprofen (British Patent 1,164,585, published Sept. 17, 1969). Such acidic agents are often irritating, and in some cases are ulcerogenic, to the gastric mucosa when administered orally. There is thus a great need for anti-inflammatory agents, for example compounds having a basic amine function, which might be expected to be non-irritating to the gastric mucosa. Although the chemical literature describes numerous types of amine-substituted compounds asserted to have anti-inflammatory activity [see for example U.S. Patents 3,770,748, patented Nov. 6, 1973 and 3,803,127, patented April 9, 1974 (N-phenylpolymethyleneimines); U.S. Patents 3,772,311, patented Nov. 13, 1973 and 3,773,772, patented Nov. 20, 1973 (polymethyleneimino-lower-alkanoyl-pyrazoles); U.S. Patent 3,773,944, patented Nov. 20, 1973 (1-[3-aminopropyl]-phthalans); U.S. Patent 3,801,594, patented April 2, 1974 (3-amino-lower-alkyl-indoles); U.S. Patent 3,810,985, patented May 14, 1974 (4-anilino-1,3,5-triazines) and French Patent 1,549,342, délivré November 4, 1968, (4-[benzoylphenylmethyl]-morpholines)], no such basic compounds are known to be commercially available, and none are known to be under advanced investigation by pharmacologists for possible commercial development. The search for an effective, non-acidic anti-inflammatory agent for commercial development has therefore continued.

The present invention relates to N-3-[R₁-(phenyl)-C(=X)]-phenyl-lower-alkyl amines, which are useful as anti-inflammatory agents, having the formula I:




- where R_1 represents hydrogen or one or two, which may be the same or different, lower-alkyl, hydroxy, lower-alkoxy, trifluoromethyl, lower-alkylmercapto, lower-alkyl-sulfinyl, lower-alkylsulfonyl or halogen selected from fluorine, chlorine and bromine; R_2 represents hydrogen, or lower-alkoxy or hydroxy in the 4-position relative to the $CHR_3CH_2-N=B$ group, or lower-alkyl in either of the 2-, 4-, 5- or 6-positions; R_3 represents hydrogen or lower-alkyl; the group $>C=X$ represents $>C=O$, $>C(R_3)OH$, $>C(R_3)H$, $>C=CH_2$, $>C=NOH$ or $>CHN(R_3)_2$ (where R_3 is only hydrogen or methyl in the last case) and $N=B$ represents one of the groups




- where R_3 represents hydrogen or lower-alkyl and is the same or different when occurring more than once, R_4 and R_5 each represent lower-alkyl; R_6 and R_7 each represent hydrogen, lower-alkyl, cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl or benzyl; Z represents O, S or $N-R_8$; R_8 represents lower-alkyl or cyclohexyl; and n represents one of the integers 1, 2 and 3.

- Preferred compounds of formula I are those where R_1 represents hydrogen or one or two, which may be the same or different, lower-alkyl, lower-alkoxy or halogen; R_2 represents hydrogen, or lower-alkoxy or hydroxy in the 4-position relative to the $CHR_3CH_2-N=B$ group; and $N=B$ represents one of the groups




- in which R_6 represents hydrogen, lower-alkyl, cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl or 3-cyclohexylpropyl; R_7 represents hydrogen; Z represents oxygen; and R_3 , R_4 and n have the meanings given above.

- Particularly preferred compounds of formula I within the ambit of the invention as described above are those where R_1 represents hydrogen or one or two, which may be the same or different, lower-alkoxy or halogen; R_2 represents hydrogen; $>C=X$ represents $>C=O$, $>CHOH$, $>CH_2$, $>C=NOH$ or $>CHNH_2$; and $N=B$ represents one of the groups



in which R_6 represents hydrogen, lower-alkyl, cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl or 3-cyclohexylpropyl; R_7 represents hydrogen; Z represents oxygen; n represents the integers 1 or 2; and R_3 and R_4 have the meanings given above.


Also within the purview of the present invention are compounds having the formula Ia:



where the group $>C=X$ represents $>C=O$ and R_3 represents lower-alkyl or where the group $>C=X$ represents $>CHNH_2$ and R_3 represents hydrogen.

As used herein, the terms lower-alkyl and lower-alkoxy mean saturated, mono-valent, aliphatic radicals, including branched chain radicals, of from one to four carbon atoms, for example methyl, ethyl, propyl, isopropyl, butyl, sec.-butyl, isobutyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec.-butoxy and isobutoxy.

The compounds of formula I in which the group $>C=X$ represents $>C(R_3)OH$ where R_3 is hydrogen are prepared by reaction of an appropriate 3- $[R_1-(phenyl)-CO]$ -phenyl-lower-alkanoyl halide of formula III (prepared by reaction of the corresponding acid of formula II with a thionyl halide) with an appropriate amine of formula IV, $H-N=B$, and reduction of the resulting 3- $[R_1-(phenyl)-CO]$ -phenyl-lower-alkanoyl-amine of formula V with a reagent effective to reduce amides to amines, for example an alkali metal aluminum hydride, a trialkylaluminum or a dialkylaluminum hydride. The method is represented by the following reaction sequence:



5

10

15

25




35

35

where R_1 , R_2 , R_3 and $N=B$ have the meanings given above, and Ts represents the *p*-toluenesulfonyl group. The reaction is preferably carried out by heating the reactants in an inert organic solvent, for example dimethylformamide or a lower-alkanol. Suitable acid-acceptors are alkali metal carbonates or bicarbonates or an excess of the amine, $H-N=B$.

The tosylates of formula VIII are in turn prepared by a sequence of reactions involving reduction, with an alkali metal borohydride, of a 3-bromophenyl-lower-alkanaldehyde to the corresponding 3-bromophenyl-lower-alkanol; reaction of the latter with dihydropyran in the absence of solvent and in the presence of a few drops of concentrated hydrochloric acid to prepare the corresponding 3-bromophenyl-lower-alkane tetrahydropyranyl ether; reaction of the latter with butyl lithium followed by an appropriate R_1 -(phenyl)-nitrile and hydrolysis of the tetrahydropyranyl ether group; and reaction of the resulting 3-benzoylphenyl-lower-alkanol with *p*-toluenesulfonyl chloride in the presence of pyridine. The method is represented by the following reaction sequence:




where R_1 , R_2 and R_3 have the meanings given above the Ts represents the *p*-toluenesulfonyl group.

The compounds of formula I where the group $>C=X$ represents $>C(R_3)OH$ where R_3 is hydrogen or lower-alkyl are prepared by reacting a 3-halophenyl-lower-alkylamine of formula IX with a lower-alkyl lithium in an aprotic organic solvent, for example diethyl ether, and reacting the resulting aryl lithium of Formula IXa directly either with a R_1 -(phenyl)-carboxaldehyde of Formula XX (to prepare the compounds wherein R_3 is hydrogen with optional production of compounds wherein $>C=X$ is $>C=O$, as described below) or R_1 -(phenyl)-carbonitrile of formula XXI (to prepare the compounds where $>C=X$ is $>C=O$, the compounds wherein $>C=X$ is $>C(H)OH$ being prepared from the latter by reduction with an alkali metal aluminum hydride as described above, or with a R_1 -(phenyl) lower-alkyl ketone of Formula XXII (to prepare the compounds where R_3 is lower-alkyl). During the course of the reaction of the aryl lithium with an aldehyde, and for reasons not completely understood, some of the carbinol product ($C=X$ is $CHOH$) is oxidized to the ketone, and in such cases it is necessary to reduce the crude product with an alkali metal borohydride as described hereinbelow.

The 3-halophenyl-lower-alkylamines of formula IX are in turn prepared by one of two methods depending upon the identity of the group $N=B$ in the final product. The compounds of formula IX where $N=B$ is a secondary amino group are prepared by reaction of the corresponding primary amine with a 3-halophenyl-lower-alkanal of formula X, followed by reduction of the resulting Schiff base with an alkali metal borohydride. The compounds of formula IX where $N=B$ is a tertiary amino group are prepared by reaction of a 3-halophenyl-lower-alkanal of formula X with a secondary


amine, conversion of the resulting 3-halophenylvinylamine of formula XI to the iminium salt having the formula XII by reaction of the former with mineral acid, and reduction of the iminium salt with an alkali metal borohydride. The condensation of the aldehyde with the amine in the latter procedure is preferably carried out in a water immiscible solvent, for example benzene, toluene or xylene, at the reflux temperature thereof under a water separator which is used to collect the water as it is produced in the reaction. The reduction of the iminium salt with an alkali metal borohydride is carried out in an inert organic solvent, for example a lower-alkanol or dimethylformamide (DMF). The overall method is represented by the reaction sequence:



where R₁, R₂, R₃, N=B and Hal have the meanings given above, and X[⊖] represents an anion of a mineral acid.

The methods described above are used to prepare the compounds of formula I where $>C=X$ is either a carbonyl group, $>C=O$, or a carbinol group, $>C(R_3)OH$, where R_3 is either hydrogen or lower-alkyl. The compounds of formula I where the group $>C=X$ has the other meanings given are prepared by simple chemical transformations involving the carbonyl or carbinol groups. Thus the compounds where the group $>C=X$ represents $>C(R_3)H$, where R_3 is either hydrogen or lower-alkyl, are prepared by catalytic reduction with hydrogen of the corresponding carbinol, $>C(R_3)OH$, in the presence of perchloric acid. A preferred catalyst is palladium-on-charcoal, and it is preferred to carry out the reaction in glacial acetic acid as solvent. Reduction is carried out at a pressure in the range from 40—100 p.s.i.

The compounds of formula I where $>C=X$ is the group $>C=CH_2$ are prepared by dehydration of the methyl carbinols, where $>C=X$ is the group




with concentrated sulfuric acid. The reaction is carried out by refluxing a solution of the carbinol and sulfuric acid in a lower-alkanol solvent.

The compounds of formula I where $>C=X$ is the group $>C=NOH$ are prepared from the corresponding ketones ($>C=X$ is $>C=O$) by heating the latter with hydroxylamine in an inert organic solvent, for example a lower-alkanol.

The compounds of formula I where $>C=X$ is the group $CHNH_2$ are prepared by reducing the corresponding oximes ($>C=X$ is $>C=NOH$) with sodium in a lower-alkanol containing from one to four carbon atoms. The compounds of formula I where $>C=X$ is $>C=NOH$, apart from their usefulness as pharmaceutically active compounds as described below, are thus also useful as intermediates for preparation of the compounds where $>C=X$ is $>CHNH_2$.

The compounds of formula I in which $>C=X$ represents $>CHN(CH_3)_2$ are prepared from the corresponding primary amines by treatment of the latter with formaldehyde in the presence of formic acid.


The compounds of formula Ia where $>C=X$ represents $>C=O$ are prepared by reaction of a 3-(phenyl-CO)-phenyl- CHR_3 halide of formula XIII with morpholine according to the reaction:



where R_3 and Hal have the meanings given above. The reaction is carried out by reacting a solution of the halide with a molar excess of morpholine at ambient temperature in an inert organic solvent, for example methanol, ethanol, isopropanol or DMF. A preferred solvent is DMF.


The compounds of formula Ia where the group $>C=X$ represents $>CHNH_2$ are prepared from the corresponding compounds where $>C=X$ represents $>C=O$ by conversion of the latter to the oxime and reduction of the latter to the amine as described above.

The amines of formula IV where $-N=B$ is the group:




are known compounds.

The amines in which —N=B is the group:




where n is 2 are also known, having been generally described in U.S. Patent 3,238,215. As described therein, they are prepared by catalytic reduction over platinum oxide of appropriate R_3 , R_6 or R_7 -substituted pyridines, which are commercially available.

The amines where N=B is the group:




where n is the integer 1 and R_7 is hydrogen are prepared by refluxing a mixture of an appropriate alkanedione, ammonium acetate and glacial acetic acid, and catalytic reduction over platinum oxide of the resulting 2- R_3 -5- R_6 -pyrrole according to the reaction sequence:




where R_3 and R_6 have the meanings given above.

Alternatively, the amines in which —N=B is the group:




where n is 1 and R_7 is hydrogen are prepared by reaction of a Grignard reagent, $R_6\text{MgHal}$, with a 4- R_3 -4-halobutyronitrile, $R_3\text{—CH—(Hal)—(CH}_2)_2\text{—CN}$; direct cyclization of the resulting 1-amino-1- R_6 -4- R_3 -4-halobutene; and catalytic reduction of the resulting 2- R_6 -5- R_3 -4,5-dihydropyrrole as indicated by the reaction sequence:



where R_3 , R_6 and Hal have the meanings given above.


The amines where $-N=B$ is the group:



5


are advantageously prepared, like the amines where $-N=B$ is the group:

5



where n is 2, by catalytic reduction over platinum oxide of the corresponding 4- R_6 -pyridine.


The amines where $-N=B$ is the group:



10

10


where R_3 and R_7 are hydrogen, n is the integer 3, and R_6 has the meanings given above are prepared by Beckmann rearrangement of an appropriate R_6 -substituted-cyclohexanone oxime and reduction, with lithium aluminum hydride, of the resulting lactam according to the reaction:




15

15

The amines of formula VI where —N=B is the group:




where Z is O are prepared according to the method described in British Patent 835,717 which comprises passing a vaporized mixture of a glycol ether having the formula




together with ammonia and hydrogen over a hydrogenation/dehydrogenation catalyst based on either nickel or cobalt at a temperature from 150 to 250° C. A preferred catalyst is nickel on kieselguhr.


The amines of formula IV in which —N=B is the group:



where Z is S are preferably prepared by the methods described by Idson et al., J. Am. Chem. Soc. 76, 2902 (1954) which involves either the reaction of sodium sulfide with an appropriate bis-2-haloethylamine:




or the reaction of ammonia with an appropriate bis-2-haloethyl sulfide:



where R_3 and R_6 have the meanings given above, and Hal represents halogen.


The 3-[R_1 -(phenyl)-CO]-phenyl-lower-alkanoic acids of formula II where R_2 is hydrogen or lower-alkyl are generally known compounds prepared by the methods described in British Patent 1,164,585. Although the compounds of formula II where R_2 is hydroxy can also be prepared by the methods used to prepare the compounds

where R_2 is hydrogen or lower-alkyl and the compounds of formula II so-prepared converted, as described above, to the final products of formula I, it is preferred to prepare the compounds of formula I where R_2 is hydroxy from a 4-lower-alkoxy-phenyl-lower-alkanoic acid by conversion of the latter to the corresponding acid halide; conversion of the latter to the corresponding 4-lower-alkoxyphenyl-lower-alkanoyl-amine by reaction of the acid halide with an amine, $H-N=B$, and reduction of the resulting amide with a reagent effective to reduce amides to amines, for example an alkali metal aluminum hydride; reaction of the resulting amine with an acid halide, $R_1-(phenyl)-CO-Hal$, using Friedel-Crafts conditions; and finally cleavage of the lower-alkoxy group to the hydroxy group, using well-known methods such as heating with hydrobromic acid. The method is represented by the following reaction sequence:



where R_1 , R_3 , R_4 , $N=B$ and Hal have the meanings given above. The reaction conditions for the first four reactions in this reaction sequence have been described above, and cleavage of the ether with hydrobromic acid is a conventional reaction well known to the organic chemist.

The 3-halophenyl-lower-alkanals of formula X are prepared via the Darzens glycidic ester condensation by reaction of a 3-halo-lower-alkanophenone with a lower-alkyl haloacetate in the presence of an alkali metal alkoxide and saponification and decarboxylation of the resulting glycidic ester. The method is represented by the following reaction sequence:



The novel compounds of the present invention are the compounds of formulae I and Ia and the acid-addition salts thereof. The compounds of formulae I and Ia in

free base form are converted to the acid-addition salt form by interaction of the base with an acid. In like manner, the free base can be regenerated from the acid-addition salt form in the conventional manner, that is by treating the salts with cold, weak aqueous bases, for example alkali metal carbonates and alkali metal bicarbonates. The bases thus regenerated can then be interacted with the same or a different acid to give back the same or a different acid-addition salt. Thus the novel bases and all of their acid-addition salts are readily interconvertible.

It will thus be appreciated that formulae I and Ia not only represent the structural configuration of the bases of formulae I and Ia but are also representative of the structural entities which are common to all of the compounds of formulae I and Ia, whether in the form of the free base or in the form of the acid-addition salts of the base. It has been found that by virtue of these common structural entities, the bases and their acid-addition salts have inherent pharmacological activity of a type to be more fully described hereinbelow. This inherent pharmacological activity can be enjoyed in useful form for pharmaceutical purposes by employing the free bases themselves or the acid-addition salts formed from pharmaceutically-acceptable acids, that is acids whose anions are innocuous to the animal organism in effective doses of the salts so that beneficial properties inherent in the common structural entity represented by the free bases is not vitiated by side effects ascribable to the anions.

In utilizing this pharmacological activity of the salts of the invention, it is preferred, of course, to use pharmaceutically acceptable salts. Although water-insolubility, high toxicity, or lack of crystalline character may make some particular salt species unsuitable or less desirable for use as such in a given pharmaceutical application, the water-insoluble or toxic salts can be converted to the corresponding pharmaceutically-acceptable bases by decomposition of the salt with aqueous base as explained above, or alternatively they can be converted to any desired pharmaceutically-acceptable acid-addition salt by double decomposition reactions involving the anion, for example by ion-exchange procedures.

Moreover, apart from their usefulness in pharmaceutical applications, the salts are useful as characterizing or identifying derivatives of the free bases or in isolation or purification procedures. Like all of the acid-addition salts, such characterizing or purification salt derivatives can, if desired, be used to regenerate the pharmaceutically-acceptable free bases by reaction of the salts with aqueous base, or alternatively can be converted to a pharmaceutically-acceptable acid-addition salt by, for example, ion-exchange procedures.

It will be appreciated from the foregoing that all of the acid-addition salts of the new bases are useful and valuable compounds, regardless of considerations of solubility, toxicity, physical form and the like, and are accordingly within the purview of the present invention.

The novel feature of the compounds of the invention, then, resides in the concept of the bases and cationic forms of the new $N\{-[R_1-(\text{phenyl})-C(=X)]\text{-phenyl-lower-alkyl}\}$ amines and not in any particular acid moiety or acid anion associated with the salt forms of the compounds; rather, the acid moieties or anions which can be associated with the salt forms are in themselves neither novel nor critical and therefore can be any acid anion or acid-like substance capable of salt formation with the bases. In fact, in aqueous solutions, the base form or water-soluble acid-addition salt form of the compounds of the invention both possess a common protonated cation or ammonium ion.

Thus appropriate acid-addition salts are those derived from such diverse acids as formic acid, acetic acid, isobutyric acid, alpha-mercaptopropionic acid, malic acid, fumaric acid, succinic acid, succinamic acid, tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, 1-naphthalene-carboxylic acid, cinnamic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, acetylenedicarboxylic acid, sorbic acid, 2-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, 2-pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesulfonic acid, isethionic acid, benzenesulfonic acid, *p*-toluenesulfonic acid, benzenesulfinic acid, butylarsonic acid, diethylphosphonic acid, *p*-aminophenylarsinic acid, phenylstibnic acid, phenylphosphinous acid, methylphosphinic acid, phenylphosphinic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, perchloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrocyanic acid, phosphotungstic acid, molybdic acid, phosphomolybdic acid, pyrophosphoric acid, arsenic acid, picric acid, picrolonic acid, barbituric acid and boron trifluoride.

The acid-addition salts are prepared by reacting the free base and acid in an organic solvent and isolating the salt directly or by concentration of the solution.

Due to the presence of at least one and as many as four asymmetric centres in

the compounds of the invention, i.e. the carbon atom adjacent the phenyl ring to which the group R_3 is attached and the various asymmetric centers in the group $-N=B$ to which the groups R_3 , R_4 , R_5 , R_6 and R_7 are attached, the compounds of the invention can exist in stereochemically isomeric forms which are all considered to be within the purview of the invention. If desired, the isolation or the production of a particular stereochemical form can be accomplished by application of general principles known in the art.

In standard pharmacological test procedures, the compounds of formulae I and Ia have been found to possess anti-inflammatory activity and are useful as anti-inflammatory agents. Certain compounds of formula I have also been found to have anti-viral activity and are thus also useful as anti-viral agents. Anti-inflammatory activity was determined using (1) the inhibition of carrageenin-induced foot edema test essentially described by Van Arman et al., J. Pharmacol. Exptl. Therap. 150, 328 (1965) as modified by Winter et al., Proc. Soc. Exp. Biol. and Med. 111, 544 (1962) and (2) a modification of the inhibition of adjuvant-induced arthritis test described by Pierson, J. Chronic Diseases 16, 863 (1963) and Glenn et al., Am. J. Vet. Res. 26, 1180 (1965).

The *in vitro* anti-viral activity of the compounds against herpes simplex viruses types 1 and 2 was demonstrated by the addition of the compounds to tissue cultures infected with herpes virus. Monolayers of tissue cultures (BSC, cell line, monkey kidney) were infected with one hundred TCID₅₀ (Tissue Culture Infectious Dose₅₀) of infectious virus. After one hour of virus adsorption, fresh maintenance medium containing various concentrations of the test compound was added to the monolayers. Cultures were then incubated at 36—37° C, and after forty-eight and seventy-two hours, cultures were examined microscopically. In the infected control tubes as well as in those containing inactive compounds, viral growth is indicated by the production of characteristic cytopathic effects with the destruction of the cells. In the presence of an active compound, cells grow normally similar to those in the tissue culture control. Simultaneously with the anti-viral evaluation, the toxicity of each compound was evaluated in separate cultures. Identical concentrations of the test compound were added to the tissue culture monolayers in the absence of virus. Those concentrations of the compound which show toxic effects on the cells were not considered in the anti-viral evaluation. The activity of the compounds was expressed in terms of the Minimal Inhibitory Concentration (MIC), where the MIC is described as the lowest concentration of the test compound which completely inhibits the growth of the virus.

The compounds of the invention can be prepared for use by incorporating them in unit dosage form as tablets or capsules for oral administration either alone or in combination with suitable adjuvants such as calcium carbonate, starch, lactose, talc, magnesium stearate and gum acacia. Still further, the compounds can be formulated for oral administration in aqueous alcohol, glycol or oil solutions or oil-water emulsions in the same manner as conventional medicinal substances are prepared.

The molecular structures of the compounds of the invention were assigned on the basis of study of their infrared, ultraviolet, and NMR spectra, and confirmed by the correspondence between calculated and found values for elementary analyses for the elements.

The following examples will further illustrate the invention without, however, limiting it thereto. All melting points are uncorrected.

Preparation of Amine Intermediates.

Preparation 1.

In three separate runs, 33.8 g. (0.20 mole) portions of 2-benzylpyridine, each in a solution of about 225 ml. of ethanol and 22 ml. of concentrated hydrochloric acid, were reduced over 4.0 g. portions of platinum oxide catalyst under about 54 p.s.i. of hydrogen at a temperature of 55—61° C. When reduction was complete in each case, the catalyst was removed by filtration, washed with small portions of ethanol, and the combined filtrates evaporated to a volume of about 80 ml. and diluted to approximately 500 ml. with boiling acetone. The solid which precipitated was collected, washed with acetone and dried giving a combined yield of 124.8 g. of 2-cyclohexylmethyl piperidine hydrochloride, m.p. 211—213° C. The free base was regenerated from the hydrochloride by neutralization of an aqueous solution of the latter with potassium carbonate, extraction of the oily base into benzene, evaporation of the benzene solution to dryness, and distillation of the residual oil *in vacuo* at 55—59° C./0.27 mm. There was thus obtained 89.4 g. of 2-cyclohexylmethylpiperidine.

Preparation 2.

A mixture of 15.52 g. (0.10 mole) of 2-phenylpyridine, 15 ml. of concentrated

hydrochloric acid and 2.0 g. of platinum oxide in 185 ml. of ethanol in a pressure bottle was heated and shaken in a Parr hydrogenator under 55 p.s.i. of hydrogen at a temperature around 60° C. When reduction was complete in about eight hours, the catalyst was removed by filtration and the filtrate concentrated to about 50 ml. and diluted with 200 ml. of acetone. The solid which separated was collected and dried to give 14.54 g. of 2-cyclohexylpiperidine hydrochloride, m.p. 251—253° C.

Preparation 3.

A mixture of 9.1 g. (0.05 mole) of 2-stilbazole (Shaw et al., J. Chem. Soc. 1933, 77—79) and 1.0 g. of platinum oxide in a solution of 240 ml. of ethanol and 10 ml. of concentrated hydrochloric acid in a pressure bottle was heated and shaken on a Parr hydrogenator under about 55 p.s.i. of hydrogen at a temperature of about 60° C. When reduction was complete in about eight hours, the catalyst was removed by filtration, the filtrate concentrated to a volume of about 50 ml. and diluted with about 200 ml. of acetone. The solid which separated was collected and dried to give 9.6 g. of 2-(2-cyclohexylethyl)-piperidine hydrochloride, m.p. 155—156° C.

Preparation 4.

A solution of 78.1 g. (0.84 mole) of 4-methylpyridine and 89.0 g. (0.84 mole) of benzaldehyde in 103 g. of acetic anhydride was heated with stirring under reflux for twenty-four hours. The mixture was then concentrated to a thick oil *in vacuo* and the residue dissolved in hot ethanol. The solid which separated was collected and recrystallized from ethanol to give 57.9 g. of 4-styrylpyridine, m.p. 131.5—133° C.

The latter (36.2 g., 0.2 mole), dissolved in 220 ml. of absolute ethanol and 30 ml. of concentrated hydrochloric acid, was reduced over 3.0 g. of platinum oxide under a hydrogen pressure of about 55 p.s.i. The product was worked up in the manner described above in Preparation 1 and isolated in the form of the hydrochloride salt to give 43.5 g. of 4-(2-cyclohexylethyl)piperidine hydrochloride, m.p. 246—248° C.

Preparation 5.

4-Phenylpyridine (15.5 g., 0.1 mole) dissolved in 185 ml. of absolute ethanol and 15 ml. of concentrated hydrochloric acid was reduced with hydrogen over 2 g. of platinum oxide under a hydrogen pressure of about 55 p.s.i. The product was worked up in the manner described above in Preparation 1 and isolated in the form of the hydrochloride salt to give 15.3 g. of 4-cyclohexylpiperidine hydrochloride. (The free base gives m.p. 106—109° C.)

Preparation 6.

To a mixture of 8.6 g. (0.36 mole) of magnesium turnings in 150 ml. of dry ether was added in small portions with cooling and stirring a solution of 45.0 g. (0.36 mole) of benzyl chloride in 75 ml. of anhydrous ether. When addition was complete, the mixture was stirred for about one hour and then treated dropwise with a solution of 26.6 g. of 4-chlorobutyronitrile in 95 ml. of ether. When addition was complete, the ether was gradually distilled off while replacing with an equal volume of toluene. The mixture was heated under reflux (at about 109° C.) for about thirty minutes, cooled to about 15° C., treated dropwise with 300 ml. of 10% aqueous ammonium chloride, filtered and the organic layer separated. The latter was washed with three 100 ml. portions of dilute hydrochloric acid, and the combined acid extracts were basified with solid potassium carbonate. Extraction of the mixture with ether and removal of the solvent from the combined organic extracts afforded an oil which was distilled *in vacuo* to give 13.05 g. of 2-benzyl-4,5-dihydropyrrole, b.p. 123—125° C./13 mm., n_D^{25} 1.5405.

The latter, dissolved in 210 ml. of ethanol and 15 ml. of concentrated hydrochloric acid was reduced with hydrogen over 2 g. of platinum oxide under a hydrogen pressure of about 50 p.s.i. The mixture was worked up in the manner described above in Preparation 1 and the product isolated in the form of the hydrochloride salt to give 16.8 g. of 2-cyclohexylmethylpyrrolidine hydrochloride, m.p. 130.5—131.5° C. (from acetone).

Preparation 7.

To a suspension of 11.2 g. (1.6 mole) of lithium wire in 600 ml. of anhydrous ether was added dropwise 125.6 g. (0.8 mole) of bromobenzene. When addition was complete, the mixture was stirred for about a half hour and then treated dropwise first with a solution of 74.4 g. (0.8 mole) of picoline in 100 ml. of anhydrous ether and then, after stirring for fifteen minutes, with a solution of 74.0 g. (0.4 mole) of 2-phenyl-

ethyl bromide in 100 ml. of ether. The mixture was stirred at ambient temperature for about twelve hours and then poured with stirring onto 300 g. of ice. When all excess lithium had reacted, the layers were separated, the aqueous layer washed with additional ether, and the combined organic portions were washed with brine, dried and taken to dryness to give a residual oil which was distilled *in vacuo* to give 41.3 g. of 2-(3-phenylpropyl)pyridine, b.p. 76—78° C./0.05 mm., n_D^{25} 1.5592.

The latter (19.7 g., 0.1 mole) dissolved in 235 ml. of ethanol and 15 ml. of concentrated hydrochloric acid was reduced with hydrogen over 2 g. of platinum oxide under a hydrogen pressure of around 55 p.s.i. at about 65° C. The product was worked up in the manner described above in Preparation 1 and isolated in the form of the hydrochloride salt to give 22.2 g. of 2-(3-cyclohexylpropyl)piperidine hydrochloride, m.p. 175—176.5° C. (from ethyl acetate).

Preparation 8.

Catalytic reduction of 3-benzylpyridine in glacial acetic acid over a platinum oxide catalyst and isolation of the product using the procedure described above in Preparation 1 affords 3-benzylpiperidine.

Preparation of Final Products.

Example 1.

A solution of 25.4 g. (0.1 mole) of α -(3-benzoylphenyl)propionic acid in 40 ml. of benzene was added to 19.8 g. (0.166 mole) of thionyl chloride and the solution refluxed for two and a half hours. The solvent was then removed *in vacuo*, and the resulting oil (28 g.) consisting of α -(3-benzoylphenyl)propionyl chloride was dissolved in 40 ml. of diethyl ether and added with stirring over a thirty minute period to a solution of 2-cyclohexylmethylpiperidine in 80 ml. of diethyl ether. The mixture was stirred for about forty-eight hours at ambient temperature, then filtered, the filter washed with ether, and the combined filtrate washed once with dilute acid, once with brine, once with aqueous potassium bicarbonate and evaporated to dryness to give 48.2 g. of 2-cyclohexylmethyl-1-[α -(3-benzoylphenyl)propionyl]piperidine.

The latter (35.5 g., 0.085 mole) was dissolved in 200 ml. of diethyl ether and the solution added dropwise with stirring to a mixture of 8.08 g. (0.21 mole) of lithium aluminum hydride in 200 ml. of ether while maintaining the temperature at 10—15° C. The reaction mixture was stirred at ambient temperature for three and one half hours, decomposed by the dropwise addition of 8.1 ml. of water, followed by 8.1 ml. of 15% sodium hydroxide and an additional 22.2 ml. of water. The mixture was then stirred for one hour, filtered, and the filtrate evaporated to dryness to give 34.0 g. of an oil, 10.5 g. of which was chromatographed over 200 g. of alumina and eluted with a solution of 60% hexane/40% ether. The early fractions were removed and evaporated to dryness to give 8.0 g. of 2-cyclohexylmethyl-1-(2-[3-(α -hydroxybenzyl)phenyl]propyl)piperidine as a viscous oil.

Anal. Calcd. for $C_{28}H_{36}NO$: C, 82.91; H, 9.69; N, 3.45.

Found: C, 83.12; H, 9.80; N, 3.49.

Examples 1A—1D.

Following a procedure similar to that described in Example 1, the following compounds of formula I were similarly prepared:

Example 1A. 2-Cyclohexylmethyl-1-(2-[3-(α -hydroxybenzyl)phenyl]ethyl)piperidine, m.p. 122—124° C. (5.8 g. from benzene/hexane) prepared by reaction of 42 g. (0.16 mole) of 3-benzoylphenylacetyl chloride (German Patent Appln. 2,243,444, published Mar. 8, 1944) with 31.7 g. (0.175 mole) of 2-cyclohexylmethylpiperidine in 150 ml. of ether in the presence of 19.4 g. (0.192 mole) of triethylamine and reduction of the resulting 2-cyclohexylmethyl-1-[(3-benzoylphenyl)acetyl]piperidine (46 g.) with 13 g. (0.35 mole) of lithium aluminum hydride in 325 ml. of ether.

Anal. Calcd. for $C_{27}H_{37}NO$: C, 82.81; H, 9.52; N, 3.58.

Found: C, 83.01; H, 9.54; N, 3.52.

Example 1B. 2,6-Dimethyl-1-(2-[3-(α -hydroxybenzyl)phenyl]ethyl)piperidine, m.p. 115—117° C. (9.53 g. from benzene/hexane) prepared by reaction of 42 g. (0.16 mole) of 3-benzoylphenylacetyl chloride with 19.8 g. (0.175 mole) of 2,6-dimethylpiperidine in 150 ml. of ether in the presence of 19.4 g. (0.092 mole) of triethylamine.

and reduction of the resulting 2,6-dimethyl-1-[(3-benzoylphenyl)acetyl]piperidine (49 g.) with 13.9 g. (0.365 mole) of lithium aluminum hydride in 300 ml. of ether.

Anal. Calcd. for $C_{22}H_{29}NO$: C, 81.69; H, 9.04; N, 4.33.

Found: C, 81.83; H, 9.04; N, 4.32.

5 *Example 1C.* 4-[2-(3-Benzoylphenyl)ethyl]morpholine hydrochloride mono- 5
hydrate, m.p. 177.5—180° C. (29.0 g. from acetone) prepared by reaction of 46.5 g.
(0.18 mole) of 3-benzoylphenylacetyl chloride with 17.2 g. (0.198 mole) of morpholine
10 in 225 ml. of methylene dichloride in the presence of 21.5 g. (0.211 mole) of triethyl- 10
amine; conversion of the resulting 49 g. of 4-[(3-benzoylphenyl)acetyl]morpholine to
the corresponding ethylene glycol ketal by reaction of the former with 125 ml. of
ethylene glycol in 1250 ml. of benzene in the presence of 2.5 g. of *p*-toluenesulfonic
acid; and reduction of the resulting ketal (58.6 g.) with 11.8 g. (0.31 mole) of lithium
15 aluminum hydride in 280 ml. of ether, followed by hydrolysis of the ketal by stirring 15
the product at 55—60° C. with 300 ml. of 1.5N hydrochloric acid for forty-five
minutes.

Anal. Calcd. for $C_{15}H_{21}NO_2 \cdot HCl \cdot H_2O$: C, 65.23; H, 6.91; Cl, 10.13.

Found: C, 65.38; H, 6.88; Cl, 10.19.

20 *Examples 1D.* *N*-[2-(3-Benzoylphenyl)ethyl]-*N*-(3-dimethylaminopropyl)amine 20
dihydrochloride hemi-hydrate, m.p. 194—197° C. (11.1 g. of the free base obtained
as a dark oil, a small amount converted to the dihydrochloride) prepared by reaction
of 46.3 g. (0.167 mole) of 3-benzoylphenylacetyl chloride with 30.2 g. (0.3 mole) of
3-dimethylaminopropylamine in 200 ml. of methylene dichloride in the presence of
20.1 g. (0.2 mole) of triethylamine; conversion of the resulting 9 g. of *N*-[(3-benzoyl-
25 phenyl)acetyl]-*N*-(3-dimethylaminopropyl)amine to the corresponding ethylene glycol 25
ketal by reaction of 15 g. of the former with 37.5 ml. of ethylene glycol in the presence
of 9.75 g. of *p*-toluenesulfonic acid in 395 ml. of benzene; and reduction of the result-
ing ketal (15.6 g.) with 3.2 g. (0.084 mole) of lithium aluminum hydride in a solution
of 50 ml. of dioxane and 50 ml. of di-*n*-butyl ether, followed by hydrolysis of the
ketal by warming it for one hour in 200 ml. of dilute hydrochloric acid at 55° C.

30 *Anal.* Calcd. for $C_{20}H_{26}N_2O \cdot 2HCl \cdot 1/2 H_2O$: C, 61.22; H, 7.43; Cl, 18.01. 30
Found: C, 61.97; H, 7.48; Cl, 17.70.

Example 2.

Following a procedure similar to that described in Example 1, 2,6-dimethyl-1-*o*-
(3-benzoylphenyl)propionyl]piperidine (14.3 g. as an oil) was prepared from 12.7 g.
35 of α -(3-benzoylphenyl)propionic acid, 10 g. (0.084 mole) of thionyl chloride, 6.22 g. 35
(0.055 mole) of 2,6-dimethylpiperidine and 6.05 g. (0.06 mole) of triethylamine, and
the resulting amide (14.3 g.) reduced with 3.9 g. (0.103 mole) of lithium aluminum
hydride in diethyl ether to give 13.2 g. of 2,6-dimethyl-1-(2-[3-(α -hydroxybenzyl)-
phenyl]propyl)piperidine as a yellow oil.

40 *Anal.* Calcd. for $C_{23}H_{31}NO$: C, 82.34; H, 8.71; N, 4.18. 40
Found: C, 82.22; H, 8.82; N, 4.15.

Examples 2A—D.

Following a procedure similar to that described in Example 1, the following com-
pounds of formula I are similarly prepared:

45 *Example 2A.* *N*-*t*-Butyl-*N*-{2-[3-(α -hydroxy-4-methyl-2-chlorobenzyl)phenyl]propyl}- 45
amine prepared by reaction of α -[3-(4-methyl-2-chlorobenzoyl)phenyl]propionyl
chloride with *t*-butylamine and reduction, with lithium aluminum hydride, of the result-
ing *N*-*t*-butyl-*N*-{ α -[3-(4-methyl-2-chlorobenzoyl)phenyl]propionyl}-amine;

50 *Example 2B.* *N* - Benzyl - *N* - *t* - butyl - *N* - {2 - [3 - (α - hydroxy - 3- 50
trifluoromethylbenzyl)phenyl]propyl}amine prepared by reaction of α -[3-(3-trifluoro-
methylbenzoyl)phenyl]propionyl chloride with *N*-benzyl-*N*-*t*-butylamine and reduc-
tion, with lithium aluminum hydride, of the resulting *N*-benzyl-*N*-*t*-butyl-*N*-{ α -[3-(3-
trifluoromethylbenzoyl)phenyl]propionyl}amine;

55 *Example 2C.* *N,N* - Di - isobutyl - *N* - {2 - [3 - (α - hydroxy - 2,4 - dichloro- 55
benzyl)phenyl]propyl}amine prepared by reaction of α -[3-(2,4-dichlorobenzoyl)-
phenyl]propionyl chloride with *N,N*-di-isobutylamine and reduction, with lithium

aluminum hydride, of the resulting N,N-di-isobutyl-N-(α -[3-(2,4-dichlorobenzoyl)-phenyl]propionyl)amine; and

5 *Example 2D.* 4-(2-Cyclohexylethyl)-1-{2-[3-(α -hydroxy-2-bromo-benzyl)-4-methylphenyl]propyl}piperidine prepared by reaction of α -[3-(2-bromobenzoyl)-4-methylphenyl]propionyl chloride with 4-(2-cyclohexylethyl)piperidine and reduction, with lithium aluminum hydride, of the resulting 4-(2-cyclohexylethyl)-1-{ α -[3-(2-bromobenzoyl)-4-methylphenyl]propionyl}piperidine. 5

Example 3.

10 To 220 g. (1.65 moles) of aluminum chloride was added with vigorous stirring over a twenty minute period 81 g. (0.67 mole) of acetophenone. The resulting mixture was treated dropwise with stirring over a forty minute period with 120 g. (0.8 mole) of bromine. When addition was complete, the mixture was stirred for an additional fifteen minutes and then extracted with four 150 ml. portions of ether. The combined ether extracts were washed once with water, once with 10% potassium bicarbonate, 15 once with saturated brine, dried over anhydrous sodium sulfate, and evaporated to dryness to give 141 g. of an oil which was distilled *in vacuo* to give 108.7 g. of 3-bromoacetophenone, b.p. 71.5—76° C./0.5 mm. 15

20 To 2,200 ml. of isopropanol in a three-necked round bottom flask flushed with nitrogen was added in pieces 60 g. (2.6 moles) of sodium. When all the sodium had dissolved, the mixture was cooled to about 7—8° C. and treated over a period of thirty minutes with a solution of 318 g. (1.6 moles) of 3-bromoacetophenone and 352 g. (2.88 moles) of ethyl chloroacetate. The mixture was stirred at 7—8° C. for five hours and then at ambient temperature for about forty-eight hours, refluxed for one hour, 25 distilled to remove about one liter of isopropanol, and the residue diluted with 1900 ml. of water and 1200 ml. of toluene and stirred. The layers were separated, the aqueous layer was extracted with additional toluene, and the combined toluene extracts were washed with saturated brine, dried, and evaporated to dryness to give 558.8 g. of a brown liquid which was combined with a solution of 70 g. of sodium hydroxide in 225 ml. of water and 1200 ml. of absolute ethanol and refluxed for about twelve hours. 30 The mixture was then taken to dryness *in vacuo* to give 575.6 g. of a solid which was dissolved in water, acidified with dilute hydrochloric acid, and the mixture extracted with benzene. The benzene extracts were taken to dryness to give 485.4 g. of material which was steam distilled affording 272.5 g. of α -(3-bromophenyl)propionaldehyde. 30

35 A solution of the latter with 465 g. (2.6 moles) of 2-cyclohexylmethylpiperidine in 6 liters of benzene was refluxed under a Dean-Stark trap for about twelve hours. The solvent was removed *in vacuo* giving 712.1 g. of an oil which was distilled *in vacuo* to remove lower boiling impurities. There was thus obtained as a higher boiling pot residue 357.2 g. of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)-1-propenyl]piperidine. 35

40 The latter (0.95 mole) was dissolved in 3 liters of hexane, and the solution cooled in an ice bath and treated with 220 ml. (1.20 moles) of 4.9N ethereal hydrogen chloride. The white gummy solid which separated, consisting of the iminium hydrochloride, was collected, filtered, washed with fresh hexane, dissolved in 3.5 liters of dimethylformamide, and the solution treated with 72 g. (1.9 moles) of sodium borohydride added in small amounts over a ten minute period. The mixture was then 45 stirred at ambient temperature for about an hour and a half, treated with one liter of 10% sodium hydroxide and 6 liters of water, and then extracted with hexane. The combined hexane extracts afforded 305.4 g. of a yellow oil which was distilled *in vacuo* to give 189.6 g. of material, b.p. 143-161° C./0.06 mm., which was redistilled at 0.5 mm. (b.p. 167—187° C.) to give 158.5 g. of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine. 50 50

Anal. Calcd. for $C_{21}H_{32}BrN$: C, 66.66; H, 8.52; Br, 21.12

Found: C, 66.71; H, 8.36; Br, 21.20.

55 A solution of the latter (37.9 g., 0.1 mole) dissolved in 80 ml. of diethyl ether was treated dropwise with 165 ml. (0.18 mole) of a 1.08M solution of n-butyl lithium in diethyl ether while maintaining the temperature around 10° C. When addition was complete, the mixture was stirred for thirty minutes at about 10° C., then at ambient temperature for one hour, refluxed for about thirty minutes, cooled once again to 10° C., and treated with a solution of 25.8 g. (0.19 mole) of 4-methoxybenzaldehyde in 50 ml. of ether while maintaining the temperature around 15—20° C. The mixture 60 was then refluxed for twenty minutes, cooled, basified by the addition of 110 ml. of 10% sodium hydroxide and stirred for ten minutes. The mixture was then filtered, the organic layer separated, and the aqueous layer extracted with additional diethyl 60

- ether. The combined organic extracts were washed with saturated brine, dried over sodium sulfate, and evaporated to dryness to give 55 g. of an oil which was dissolved in 150 ml. of absolute methanol. The solution was treated cautiously with 7 g. of sodium borohydride, stirred at 15° C. for twenty minutes, carefully acidified by the addition of 150 ml. of sulfuric acid and extracted three times with hexane. The aqueous solution was basified with 150 ml. of 10% sodium hydroxide, diluted with water and extracted four times with hexane. The combined hexane extracts afforded 32 g. of an oil which was chromatographed on 500 g. of alumina using 1.5% isopropylamine in hexane as eluent. The first 3 liters of eluate were collected and set aside, and the next 3.7 liters collected and evaporated to dryness to give 20.4 g. of 2-cyclohexylmethyl-1-{2-[3-(α -hydroxy-4-methoxybenzyl)phenyl]propyl}piperidine as a yellow oil.

Anal. Calcd. for $C_{29}H_{41}NO_2$: C, 79.95; H, 9.49; N, 3.22.
Found: C, 78.88; H, 9.43; N, 3.07.

Examples 3A—3H.

- Following a procedure similar to that described in Example 3, the following compounds of formula I are prepared:

- Example 3A.* 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 3 - chlorobenzyl) - phenyl]propyl}piperidine (26.8 g. as a yellow oil) prepared by reaction of 37.8 g. (0.1 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine with 0.19 mole of n-butyl lithium and reaction of the resulting lithio derivative with 28.0 g. (0.2 mole) of 3-chlorobenzaldehyde in about 250 ml. of diethyl ether.

Anal. Calcd. for $C_{28}H_{38}ClNO$: C, 76.42; H, 8.70; N, 3.18.
Found: C, 76.64; H, 8.98; N, 3.16.

- Example 3B.* 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxybenzyl)phenyl] - propyl}pyrrolidine (5.3 g. as a tan viscous oil) prepared by reaction of 10.8 g. (0.03 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]pyrrolidine with 0.06 mole of n-butyl lithium and reaction of the resulting lithio derivative with 7.0 g. (0.066 mole) of benzaldehyde.

Anal. Calcd. for $C_{37}H_{37}NO$: C, 82.81; H, 9.52; N, 3.58.
Found: C, 82.29; H, 10.03; N, 3.51.

- Example 3C.* 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 3,4 - dichlorobenzyl)phenyl]propyl}piperidine (12.3 g. as an oil) prepared by reaction of 37.8 g. (0.1 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine with 0.19 mole of n-butyl lithium and reaction of the resulting lithio derivative with 35.1 g. (0.2 mole) of 3,4-dichlorobenzaldehyde in diethyl ether.

- Example 3D.* 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 2 - chlorobenzyl)phenyl]propyl}piperidine (30.7 g. as an oil) prepared by reaction of 37.8 g. (0.1 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine with 0.19 mole of n-butyl lithium and reaction of the resulting lithio derivative with 28.0 g. (0.2 mole) of 2-chlorobenzaldehyde in diethyl ether.

- Example 3E.* 2 - (3 - Cyclohexylpropyl) - 1 - {2 - [3 - (α - hydroxybenzyl) - phenyl]propyl}piperidine (5.4 g. as a viscous oil) prepared by reaction of 12.2 g. (0.03 mole) of 2-(3-cyclohexylpropyl)-1-[2-(3-bromophenyl)propyl]piperidine with 0.68 mole of n-butyl lithium and reaction of the resulting lithio derivative with 7.0 g. (0.06 mole) of benzaldehyde in diethyl ether.

Anal. Calcd. for $C_{33}H_{43}NO$: C, 83.09; H, 9.99; N, 3.23.
Found: C, 82.92; H, 10.26; N, 3.19.

- Example 3F.* 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 4 - methylmercaptobenzyl)phenyl]propyl}piperidine prepared by reaction of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine with n-butyl lithium and reaction of the resulting lithio derivative with 4-methylmercaptobenzaldehyde.

- Examples 3G.* 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 4 - methylsulfonylbenzyl)phenyl]propyl}piperidine prepared by reaction of 2-cyclohexylmethyl-1-{2-[3-(α -hydroxy-4-methylmercaptobenzyl)phenyl]propyl}piperidine described in Example 3F with one molar equivalent amount of hydrogen peroxide in formic acid.

Example 3H. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 4 - methylsulfonylbenzyl)phenyl]propyl}piperidine prepared by reaction of 2-cyclohexylmethyl-

1-{2-[3-(α -hydroxy-4-methylmercaptobenzyl)phenyl]propyl}piperidine described in Example 3F with two molar equivalents of hydrogen peroxide in formic acid.

Example 4.

Following a procedure similar to that described in Example 3, 18.9 g. (0.05 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine was reacted with 0.1 mole of n-butyl lithium in diethyl ether and the resulting lithio derivative reacted directly with 12.3 g. (0.103 mole) of 4-methylbenzaldehyde to give 16.9 g. of 2-cyclohexylmethyl-1-{2-[3-(α -hydroxy-4-methylbenzyl)phenyl]propyl}piperidine as a yellow oil.

Anal. Calcd. for $C_{29}H_{41}NO$: C, 83.00; H, 9.85; N, 3.34.
Found: C, 83.04; H, 10.01; N, 3.31.

Example 5.

Following a procedure similar to that described in Example 3 above, 18.9 g. (0.05 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine was reacted with 0.1 mole of n-butyl lithium in diethyl ether and the resulting lithio derivative reacted directly with 15.5 g. (0.11 mole) of 4-chlorobenzaldehyde. The crude product was reduced with 4.5 g. (0.12 mole) of sodium borohydride in methanol to give 16.6 g. of 2-cyclohexylmethyl-1-{2-[3-(α -hydroxy-4-chlorobenzyl)phenyl]propyl}piperidine as an oil.

Anal. Calcd. for $C_{28}H_{38}ClNO$: C, 76.42; H, 8.70; Cl, 8.06.
Found: C, 76.82; H, 8.76; Cl, 8.14.

Following a procedure similar to that described in Example 5, the following compound of formula I was similarly prepared:

Example 5A. 2-Cyclohexylmethyl-1-{2-[3-(α -hydroxy-2,6-dichlorobenzyl)phenyl]propyl}piperidine (yellow oil) prepared by reaction of 18.9 g. (0.05 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine with 0.1 mole of butyl lithium in diethyl ether followed by 19.2 g. (0.11 mole) of 2,6-dichlorobenzaldehyde to give 19.3 g. of product.

Anal. Calcd. for $C_{28}H_{37}Cl_2NO$: C, 70.87; H, 7.86; Cl, 14.94.
Found: C, 71.06; H, 8.08; Cl, 14.81.

Example 6.

Following a procedure similar to that described in Example 3, 37.8 g. (0.1 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine was reacted with 0.18 mole of n-butyl lithium in diethyl ether and the resulting lithio derivative reacted directly with 27 g. (0.23 mole) of acetophenone to give 11.8 g. of 2-cyclohexylmethyl-1-{2-[3-(α -hydroxy- α -methylbenzyl)phenyl]propyl}piperidine as a yellow oil.

Anal. Calcd. for $C_{29}H_{41}NO$: C, 83.00; H, 9.85; N, 3.34.
Found: C, 83.34; H, 9.97; N, 3.23.

Example 7.

A solution of 0.15 mole of n-butyl lithium in 90 ml. of diethyl ether was prepared by addition of 20.5 g. of n-butyl bromide in 30 ml. of ether to 2.58 g. (0.375 mole) of lithium in 60 ml. of diethyl ether. Sufficient volume of the solution to provide 0.093 mole was added to a solution of 19.4 g. (0.051 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine (described above in Example 3) in 100 ml. of ether. The mixture was stirred for thirty minutes while maintaining the temperature below 10° C., refluxed for thirty minutes, cooled once again below 10° C., treated over a ten minute period with a solution of 13.3 g. (0.10 mole) of 4-methoxybenzonitrile in 80 ml. of ether, stirred for an additional hour and a half at below 10° C., then stirred overnight at ambient temperature and treated with 110 ml. of a solution prepared by dissolving 9 ml. of concentrated sulfuric acid in 45 ml. of water and 108 ml. of dioxane. The solution was refluxed for two hours, cooled, basified with 100 ml. of 10% sodium hydroxide, the layers separated, and the aqueous layer extracted with ether. The ether extracts were washed with brine, dried and taken to dryness to give 32.6 g. of material which was dissolved in hexane and extracted with a solution of 8 ml. of concentrated sulfuric acid, 136 ml. of water and 144 ml. of methanol. The extracts were rendered basic with 10% sodium hydroxide, the mixture extracted once

- again with hexane, and the hexane extracts washed with brine, dried and taken to dryness to give 28.1 g. of material which was chromatographed on 400 g. of alumina and eluted with 50% benzene/50% hexane. The first 1750 ml. of eluate was taken to dryness, the residue heated *in vacuo* at 0.1 mm/220° C. (bath temperature) to drive off some 4-methoxybenzonitrile, and the residue once again chromatographed on alumina (250 g.) using 15% ether/85% hexane. The first 400 ml. of eluate was discarded and the next 1200 ml., on evaporation to dryness, afforded 7.1 g. of 2-cyclohexylmethyl - 1 - {2 - [3 - (4 - methoxybenzoyl)phenyl]propyl}piperidine as a yellow oil.
- Anal.* Calcd. for $C_{29}H_{39}NO_2$: C, 80.33; H, 9.07; N, 3.23.
Found: C, 80.50; H, 9.17; N, 3.14.

Examples 7A—7L.

Following a procedure similar to that described in Examples 3, 4 and 5, the following compounds of formula I are similarly prepared:

- Example 7A.* 2 - Cyclohexylmethyl - 1 - [2 - (3 - benzoylphenyl)propyl]pyrrolidine, (viscous amber liquid) prepared by reaction of 21.3 g. (0.1 mole) of α -(3-bromophenyl)propionaldehyde with 31.4 g. (0.2 mole) of 2-cyclohexylmethylpiperidine in benzene; conversion of the resulting 33.7 g. of 1-[2-(3-bromophenyl)-1-propenyl]pyrrolidine to the iminium chloride with ethereal hydrogen chloride; reduction of the iminium chloride (34.0 g.) with 6.4 g. (0.17 mole) of sodium borohydride in dimethylformamide; reaction of 9.8 g. (0.027 mole) of the resulting (18.8 g.) 2-cyclohexylmethyl - 1 - [2 - (3 - bromophenyl)propyl]pyrrolidine (b.p. 135—136° C./0.02 mm.) with 0.05 mole of butyl lithium followed by 6.2 g. (0.06 mole) of benzonitrile in diethyl ether and decomposition of the product with a solution of 4 ml. of concentrated sulfuric acid in 20 ml. of water and 50 ml. of dioxane to give 5.1 g. of product.

Anal. Calcd. for $C_{27}H_{35}NO$: C, 83.24; H, 9.06; N, 3.60.
Found: C, 82.77; H, 9.05; N, 3.64.

- Example 7B.* 2 - Cyclohexylmethyl - 1 - {2 - [3 - (4 - fluorobenzoyl)phenyl]propyl}piperidine (yellow oil) prepared by reaction of 18.9 g. (0.05 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine with 0.1 mole of butyl lithium in diethyl ether followed by 12.8 g. (0.11 mole) of 4-fluorobenzonitrile and decomposition of the product with a solution of 3.8 ml. of concentrated sulfuric acid in 19 ml. of water and 45 ml. of dioxane to give 6.5 g. of product.

Anal. Calcd. for $C_{28}H_{36}FNO$: C, 79.77; H, 8.61; N, 3.32.
Found: C, 79.60; H, 8.76; N, 3.51.

- Example 7C.* 2 - Cyclohexylmethyl - 1 - {2 - [3 - (4 - methylbenzoyl)phenyl]propyl}piperidine (9.7 g. as a yellow oil) prepared by reaction of 18.9 g. (0.05 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine with 0.1 mole of butyl lithium in diethyl ether followed by 12.4 g. (0.11 mole) of 4-methylbenzonitrile and decomposition of the product with a solution of 3.8 ml. of concentrated sulfuric acid in 19 ml. of water and 45 ml. of dioxane to give 9.7 g. of product.

Anal. Calcd. for $C_{29}H_{39}NO$: C, 83.40; H, 9.41; N, 3.35.
Found: C, 83.34; H, 9.61; N, 3.30.

- Example 7D.* 2 - (3 - Cyclohexylpropyl) - 1 [2 - (3 - benzoylphenyl)propyl]piperidine (yellow oil) prepared by reaction of 12.2 g. (0.03 mole) of 2-(3-cyclohexylpropyl)-1-[2-(3-bromophenyl)propyl]piperidine with 0.06 mole of butyl lithium in diethyl ether followed by 7.2 g. (0.07 mole) of benzonitrile and decomposition of the product with a solution of 8.3 ml. of concentrated sulfuric acid in 42 ml. of water and 100 ml. of dioxane to give 6.2 g. of product.

Anal. Calcd. for $C_{30}H_{41}NO$: C, 83.47; H, 9.57; N, 3.24.
Found: C, 83.28; H, 9.77; N, 3.05.

- Example 7E.* 2 - Cyclohexyl - 1 - [2 - (3 - benzoylphenyl)propyl]piperidine (light tan oil) prepared by reaction of 12.7 g. (0.035 mole) of 2-cyclohexyl-1-[2-(3-bromophenyl)propyl]piperidine with 0.07 mole of butyl lithium in diethyl ether

followed by 8.9 g. (0.077 mole) of benzonitrile and decomposition of the product with a solution of 9 ml. of concentrated sulfuric acid in 45 ml. of water and 100 ml. of dioxane to give 6.1 g. of product.

Anal. Calcd. for $C_{27}H_{35}NO$: C, 83.24; H, 9.06; N, 3.60.
Found: C, 83.16; H, 9.16; N, 3.44.

Example 7F. 2 - (2 - Cyclohexylethyl) - 1 - [2 - (3 - benzoylphenyl)propyl]-piperidine (pale tan liquid) prepared by reaction of 13.7 g. (0.035 mole) of 2-(2-cyclohexylethyl)-1-[2-(3-bromophenyl)propyl]piperidine with 0.07 mole of butyl lithium in diethyl ether followed by 8.9 g. (0.077 mole) of benzonitrile and decomposition of the product with a solution of 9 ml. of concentrated sulfuric acid in 45 ml. of water and 100 ml. of dioxane to give 8.9 g. of product.

Anal. Calcd. for $C_{29}H_{39}NO$: C, 83.40; H, 9.41; N, 3.35.
Found: C, 83.57; H, 9.40; N, 3.35.

Example 7G. 8 - [2 - (3 - Benzoylphenyl)propyl] - 1,4 - dioxo - 8 - azaspiro[4,5]decane (pale yellow oil) prepared by reaction of 10.6 g. (0.05 mole) of α -(3-bromophenyl)propionaldehyde with 14.3 g. (0.1 mole) of 1,4-dioxo-8-azaspiro[4,5]decane in benzene; conversion of the resulting 15.7 g. of 8-[2-(3-bromophenyl)-1-propenyl]1,4-dioxo-8-azaspiro[4,5]decane to the iminium chloride with ethereal hydrogen chloride; reduction of the iminium chloride with 3.8 g. (0.08 mole) of sodium borohydride in dimethylformamide; reaction of the resulting 17.5 g. (0.05 mole) of 8-[2-(3-bromophenyl)propyl]-1,4-dioxo-8-azaspiro[4,5]decane with 0.1 mole of butyl lithium followed by 15.5 g. (0.15 mole) of benzonitrile in diethyl ether and decomposition of the product with a solution of 6 ml. of concentrated sulfuric acid in 30 ml. of water and 72 ml. of dioxane to give 5.1 g. of product.

Anal. Calcd. for $C_{23}H_{27}NO_2$: C, 75.58; H, 7.45; N, 3.83.
Found: C, 75.60; H, 7.69; N, 3.87.

Example 7H. 4 - [2 - (3 - Benzoylphenyl)propyl]morpholine (pale yellow oil) prepared by reaction of 21.3 g. (0.1 mole) of α -(3-bromophenyl)propionaldehyde with 17.4 g. (0.2 mole) of morpholine in benzene; conversion of the resulting 27.3 g. of 4-[2-(3-bromophenyl)-1-propenyl]morpholine to the iminium chloride with ethereal hydrogen chloride; reduction of the iminium chloride with 7.6 g. (0.2 mole) of sodium borohydride in dimethylformamide; reaction of the resulting 19 g. of 4-[2-(3-bromophenyl)propyl]morpholine (b.p. 99—120° C./0.09 mm., $n_D^{24} = 1.5477$) with 0.1 mole of butyl lithium followed by 15.5 g. (0.15 mole) of benzonitrile in diethyl ether and decomposition of the product with 150 ml. of a solution made by dissolving 6 ml. of concentrated sulfuric acid in 30 ml. of water and 72 ml. of dioxane to give 7.5 g. of product.

Anal. Calcd. for $C_{20}H_{23}NO_2$: C, 77.64; H, 7.49; N, 4.53.
Found: C, 77.62; H, 7.37; N, 4.71.

A small amount of the free base was converted to the hydrochloride salt to give 4 - [2 - (3 - benzoylphenyl)propyl]morpholine hydrochloride monohydrate, m.p. 151—155° C.

Anal. Calcd. for $C_{20}H_{23}NO_2 \cdot HCl \cdot H_2O$: C, 66.02; H, 7.20; Cl, 9.74.
Found: C, 66.37; H, 7.24; Cl, 9.59.

Example 7J. 2,6 - Dimethyl - 4 - [2 - (3 - benzoylphenyl)propyl]morpholine cyclohexanesulfamate prepared by reaction of 21.3 g. (0.1 mole) of α -(3-bromophenyl)propionaldehyde with 23 g. (0.2 mole) of 2,6-dimethylmorpholine in benzene; conversion of the resulting 28.4 g. of 2,6-dimethyl-4-[2-(3-bromophenyl)-1-propenyl]morpholine to the iminium chloride with ethereal hydrogen chloride; reduction of the iminium chloride with 10 g. (0.26 mole) of sodium borohydride in dimethylformamide; reaction of the resulting 15.5 g. of 2,6-dimethyl-4-[2-(3-bromophenyl)propyl]-morpholine (b.p. 125—129° C./0.01 mm., $n_D^{24} = 1.5294$) with 0.1 mole of butyl lithium followed by 11 g. (0.11 mole) of benzonitrile in diethyl ether and decomposition of the product with 150 ml. of a solution prepared by dissolving 45 ml. of concentrated

sulfuric acid in 225 ml. of water and 540 ml. of dioxane. The product was converted to the cyclohexanesulfamate salt which was recrystallized from acetone to give 7.7 g. of product, m.p. 156—158° C.

Anal. Calcd. for $C_{22}H_{27}NO_2 \cdot C_6H_{13}NO_3S$: C, 65.08; H, 7.80; S, 6.20.
Found: C, 64.86; H, 7.72; S, 6.22.

Example 7K. 2 - Cyclohexylmethyl - 1 - [2 - (3 - benzoyl - 2 - methylphenyl)-ethyl]piperidine prepared by reaction of 2-bromo-6-bromomethyltoluene [described by Lindsay et al., J. Am. Chem. Soc. 83, 943—949 (1961)] with potassium cyanide in refluxing ethanol; reduction of the resulting (3-bromo-2-methylphenyl)acetonitrile with diisobutylaluminum hydride; reaction of the resulting (3-bromo-2-methylphenyl)-acetaldehyde with 2-cyclohexylmethylpiperidine in refluxing benzene under a Dean-Stark trap; reduction with sodium borohydride of the iminium hydrochloride of the resulting 2 - cyclohexylmethyl - 1 - [2 - (3 - bromo - 2 - methylphenyl) - 1 - ethenyl]-piperidine; and reaction of the resulting 2-cyclohexylmethyl-1-[2-(3-bromo-2-methylphenyl)ethyl]piperidine with n-butyl lithium in diethyl ether followed by reaction of the resulting lithio derivative with benzonitrile.

Example 7I. 4 - [2 - (3 - Benzoyl - 2 - methylphenyl)ethyl]morpholine prepared by reaction of (3-bromo-2-methylphenyl)acetaldehyde with morpholine in refluxing benzene under a Dean-Stark trap; reduction with sodium borohydride of the iminium hydrochloride of the resulting 4-[2-(3-bromo-2-methylphenyl)-1-ethenyl]morpholine; and reaction of the resulting 4-[2-(3-bromo-2-methylphenyl)ethyl]morpholine with n-butyl lithium in diethyl ether followed by reaction of the resulting lithio derivative with benzonitrile.

Example 8.

Following a procedure similar to that described in Example 7, 18.9 g. (0.05 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine was reacted with 0.095 mole of n-butyl lithium in diethyl ether and the resulting lithio derivative reacted directly with 12.4 g. (0.106 mole) of 2-methylbenzonitrile to give 4.85 g. of 2-cyclohexylmethyl-1-[2-[3-(2-methylbenzoyl)phenyl]propyl]piperidine as a yellow oil.

Anal. Calcd. for $C_{29}H_{39}NO$: C, 83.40; H, 9.41; N, 3.35.
Found: C, 83.14; H, 9.54; N, 3.67.

Example 9.

Following a procedure similar to that described in Example 7, 18.9 g. (0.05 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine was reacted with 0.095 mole of n-butyl lithium in diethyl ether and the resulting lithio derivative reacted directly with 12.4 g. (0.106 mole) of 3-methylbenzonitrile to give 10.7 g. of 2-cyclohexylmethyl-1-[2-[3-(3-methylbenzoyl)phenyl]propyl]piperidine as a yellow oil.

Anal. Calcd. for $C_{29}H_{39}NO$: C, 83.40; H, 9.41; N, 3.35.
Found: C, 83.06; H, 9.38; N, 3.48.

Example 10.

A solution of 13.0 g. (0.032 mole) of 2-cyclohexylmethyl-1-[2-[3-(α -hydroxybenzyl)phenyl]propyl]piperidine (described above in Example 1) in 167 ml. of glacial acetic acid and 33 ml. of perchloric acid was placed in a Parr hydrogenator and reduced over 3.5 g. of 10% palladium-on-charcoal at ambient temperature under a hydrogen pressure of 54 p.s.i. When reduction was complete, the catalyst was removed by filtration, the filtrate was taken to dryness, and the residue rendered basic with 10% sodium hydroxide and extracted four times with hexane. The combined hexane extracts were dried, taken to dryness, and the residue chromatographed on 220 g. of alumina, and eluted with 10% ether/89% hexane/1% isopropylamine. The first 350 ml. of eluate when taken to dryness afforded 10.6 g. of 2-cyclohexylmethyl-1-[2-(3-benzylphenyl)propyl]piperidine as a yellow oil.

Anal. Calcd. for $C_{28}H_{39}N$: C, 86.32; H, 10.09; N, 3.59.
Found: C, 86.18; H, 10.34; N, 3.51.

Example 11.

Following a procedure similar to that described in Example 10, 11.1 g. (0.027 mole) of 2-cyclohexylmethyl-1-[2-[3-(α -hydroxy- α -methylbenzyl)phenyl]propyl]-

piperidine (described in Example 6) dissolved in 180 ml. of glacial acetic acid and 20 ml. of 72% perchloric acid was reduced with hydrogen over 0.8 g. of palladium-on-charcoal to give 10.3 g. of 2-cyclohexylmethyl-1-[2-[3-(α -methylbenzyl)phenyl]propyl]piperidine as a yellow oil.

5 *Anal.* Calcd. for $C_{28}H_{41}N$: C, 86.29; H, 10.24; N, 3.47.
 Found: C, 86.04; H, 10.21; N, 3.70.

Example 12.

10 A solution of 26.8 g. (0.066 mole) of 2-cyclohexylmethyl-1-[2-[3-(α -hydroxybenzyl)phenyl]propyl]piperidine (described above in Example 1) in 140 ml. of benzene was vigorously stirred and cooled to 16° C. and then treated dropwise over a period of ten minutes with 58 ml. of a solution prepared by dissolving 26.7 g. of chromium trioxide in 23 ml. of concentrated sulfuric acid and diluting with water to 100 ml. The mixture was stirred with cooling for about one hour and forty-five minutes, the benzene layer removed, and the aqueous layer made basic by addition of 120 ml. of 10% sodium hydroxide and extracted with benzene. The organic extracts, on washing 15 once with dilute alkali, once with brine, and exaporation to dryness, afforded 21.8 g. of an oil which was chromatographed over 300 g. of alumina using 3% isopropylamine in hexane as eluent. The first 600 ml. of eluate was collected and taken to dryness to give 16.2 g. of 2-cyclohexylmethyl-1-[2-(3-benzoylphenyl)propyl]piperidine as a pale yellow viscous oil. 20

Anal. Calcd. for $C_{28}H_{37}NO$: C, 83.33; H, 9.23; N, 3.47.
 Found: C, 83.30; H, 9.33; N, 3.45.

Example 13.

25 Following a procedure similar to that described in Example 12, 15.2 g. (0.39 mole) of 2,6-dimethyl-1-[2-[3-(α -hydroxybenzyl)phenyl]propyl]piperidine (described above in Example 2) was oxidized with 34 ml. of a solution prepared by dissolving 13.4 g. of chromium trioxide in 11.5 ml. of concentrated sulfuric acid and dilution with water to 50 ml. The product, in the form of the free base, was purified by chromatographing on alumina using 10% ether/3% isopropylamine/87% hexane as eluent. There was thus obtained 4.8 g. of 2,6-dimethyl-1-[2-(3-benzoylphenyl)propyl]piperidine as a colorless viscous oil. 30

Anal. Calcd. for $C_{28}H_{37}NO$: C, 82.34; H, 8.71; N, 4.18.
 Found: C, 82.23; H, 8.82; N, 4.15.

Examples 13A—13G.

35 Proceeding in a manner similar to that described in Examples 1 and 12, the following compounds of formula I are obtained:

Example 13A. 2-Methyl-1-[2-(3-benzoylphenyl)propyl]hexamethylenimine prepared by reaction of α -(3-benzoylphenyl)propionyl chloride with 2-methyl-hexamethylenimine [Mueller et al., *Monatsh.* 61, 212—218 (1932)]; reduction with 40 lithium aluminum hydride of the resulting 2-methyl-1-[α -(3-benzoylphenyl)propionyl]-hexamethylenamine; and chromic acid oxidation of the resulting 2-methyl-1-[2-(3-(α -hydroxybenzyl)phenyl)propyl]hexamethylenimine.

Example 13B. 4-Cyclohexyl-1-[2-(3-benzoylphenyl)propyl]piperidine prepared by reaction of α -(3-benzoylphenyl)propionyl chloride with 4 cyclohexyl-piperidine; reduction with lithium aluminum hydride of the resulting 4-cyclohexyl-1-[α -(3-benzoylphenyl)propionyl]piperidine; and chromic acid oxidation of the resulting 4-cyclohexyl-1-(α -hydroxybenzyl)phenyl]propyl]piperidine. 45

Example 13C. 3-Butyl-4-[2-(3-benzoylphenyl)propyl]morpholine prepared by reaction of α -(3-benzoylphenyl)propionyl chloride with 3-butylmorpholine; reduction with lithium aluminum hydride of the resulting 3-butyl-4-[α -(3-benzoylphenyl)propionyl]morpholine; and chromic acid oxidation of the resulting 3-butyl-4-[2-(3-(α -hydroxybenzyl)phenyl)propyl]morpholine. 50

Example 13D. 3-Ethyl-4-[2-(3-benzoylphenyl)propyl]thiomorpholine prepared by reaction of α -(3-benzoylphenyl)propionyl chloride with 3-ethylthiomorpholine; conversion of the resulting 3-ethyl-4-[α -(3-benzoylphenyl)propionyl]thiomorpholine to the corresponding ethylene glycol ketal; reduction with lithium aluminum hydride of the resulting ketal; and hydrolysis with dilute mineral acid of the resulting 3-ethyl-4-[2-(3-benzoylphenyl)propyl]thiomorpholine ethylene glycol ketal. 55

Example 13E. 4-Methyl-1-[2-(3-benzoylphenyl)propyl]piperazine prepared by reaction of α -(3-benzoylphenyl)propionyl chloride with 1-methylpiperazine; reduction with lithium aluminum hydride of the resulting 4-methyl-1- $[\alpha$ -(3-benzoylphenyl)propionyl]piperazine; and chromic acid oxidation of the resulting 4-methyl-1-{2-[3-(α -hydroxybenzyl)phenyl]propyl}piperazine.

Example 13F. 3-Benzyl-1-[2-(3-benzoylphenyl)propyl]piperidine prepared by reaction of α -(3-benzoylphenyl)propionyl chloride with 3-benzylpiperidine; reduction with lithium aluminum hydride of the resulting 3-benzyl-1- $[\alpha$ -(3-benzoylphenyl)propionyl]piperidine; and chromic acid oxidation of the resulting 3-benzyl-1-{2-[3-(α -hydroxybenzyl)phenyl]propyl}piperidine.

Example 13G. N - [5 - (N',N' - Dimethylamino) - 2 - pentyl] - N - [2 - (3-benzoylphenyl)propyl]amine prepared by reaction of α -(3-benzoylphenyl)propionyl chloride with 5-(N',N'-dimethylamino)-2-pentylamine; reduction with lithium aluminum hydride of the resulting N-[5-(N',N'-dimethylamino)-2-pentyl]-N- $[\alpha$ -(3-benzoylphenyl)propionyl]amine; and chromic acid oxidation of the resulting N-[5-(N',N' - dimethylamino) - 2 - pentyl] - N - {2 - [3 - (α - hydroxybenzyl)phenyl]-propyl}amine.

Example 14.

Following a procedure similar to that described in Example 7, 5.0 g. (13.2 mole) of 2-cyclohexylmethyl-1-[2-(3-bromophenyl)propyl]piperidine was reacted with 0.026 mole of n-butyl lithium in diethyl ether and the resulting lithio derivative reacted directly with benzonitrile to give 4.0 g. of 2-cyclohexylmethyl-1-[2-(3-benzoylphenyl)propyl]piperidine identical with the material described in Example 12.

Example 15.

A mixture of 37.5 g. (0.093 mole) of 2-cyclohexylmethyl-1-[2-(3-benzoylphenyl)propyl]piperidine (described in Examples 12 and 14 above) and 10.0 g. (0.14 mole) of hydroxylamine in 125 ml. of 95% ethanol and 25 ml. of water was treated with stirring with 19.4 g. of powdered sodium hydroxide and the mixture refluxed for a half hour. The mixture was then cooled, diluted with hexane, the aqueous layer separated, and the organic layer, after drying, was evaporated to dryness to give 41.6 g. of a yellow oil which was chromatographed on alumina in 30:70 diethyl ether/hexane to give 37.3 g. of 2-cyclohexylmethyl-1-[2-(3-benzoylphenyl)propyl]piperidine oxime as an oil.

Anal. Calcd. for $C_{28}H_{38}N_2O$: C, 80.33; H, 9.15; N, 6.69.

Found: C, 80.03; H, 9.42; N, 6.44.

Examples 15A—15C.

Following a procedure similar to that described in Example 15, the following compounds of formula I were similarly prepared:

Example 15A. 4-[2-(3-Benzoylphenyl)ethyl]morpholine oxime (m.p. 117—134° C., from benzene/hexane) prepared by reacting 18.15 g. (0.05 mole) of 4-[2-(3-benzoylphenyl)ethyl]morpholine hydrochloride with 5.6 g. (0.08 mole) of hydroxylamine hydrochloride in the presence of 12.5 g. (0.31 mole) of sodium hydroxide in 70 ml. of ethanol and 18.5 ml. of water to give 14.06 g. of product.

Anal. Calcd. for $C_{19}H_{22}N_2O_2$: C, 73.52; H, 7.14; N, 9.03.

Found: C, 73.79; H, 7.26; N, 8.72.

Example 15B. 4-(3-Benzoylphenyl)methylmorpholine oxime (m.p. 145—167° C.) prepared by reaction of 28.62 g. (0.09 mole) of 4-(3-benzoylphenyl)methylmorpholine hydrochloride with 9.63 g. (0.14 mole) of hydroxylamine hydrochloride in the presence of 21.68 g. (0.54 mole) of sodium hydroxide in 35 ml. of ethanol and 27 ml. of water to give 13.9 g. of product.

Example 15C. 4 - [2 - (3 - Benzoylphenyl)propyl]morpholine oxime (m.p. 117—130° C., from isopropanol) prepared by reaction of 27 g. (0.078 mole) of 4-[2-(3-benzoylphenyl)propyl]morpholine hydrochloride with 8.2 g. (0.117 mole) of hydroxylamine hydrochloride in the presence of 18.8 g. (0.47 mole) of sodium hydroxide in 115 ml. of ethanol and 27 ml. of water to give 3.2 g. of product.

Example 16.

A solution of 17 g. (0.041 mole) of the 2-cyclohexylmethyl-1-[2-(3-benzoyl-

phenyl)propyl]piperidine oxime described above in Example 15 in 110 ml. of ethanol was brought to reflux and treated with 10 g. (0.043 mole) of sodium metal, added in small pieces. Refluxing was continued until all sodium had dissolved, and the solution was then cooled, diluted with 140 ml. of water, evaporated to a volume of about 150 ml. *in vacuo*, and then extracted with three portions of benzene. Evaporation of the benzene extracts to dryness afforded 14.2 g. of an oil which was converted to the acetate salt by dissolving in chloroform, adding glacial acetic acid and evaporation to dryness. The acetate salt was again dissolved in chloroform and chromatographed on alumina, eluting with chloroform. The acetate hydrolyzed on the column, and the free base obtained from the eluate was dissolved in ethanol, and the solution acidified with ethereal hydrogen chloride and evaporated to dryness to give 6.38 g. of 2-cyclohexylmethyl-1-{2-[3-(α -aminobenzyl)phenyl]propyl}piperidine dihydrochloride, m.p. 167—195° C.

Anal. Calcd. for $C_{28}H_{41}N_2 \cdot 2HCl$: N, 5.87; Cl, 14.85.
Found: N, 5.61; Cl, 14.66.

Examples 16A—16C.

Following a procedure similar to that described in Example 16, the following compounds of formulae I and Ia were similarly prepared.

Example 16A. 4-{2-[3-(α -Aminobenzyl)phenyl]ethyl}morpholine dihydrochloride, m.p. 260—263° C. (15.42 g. from methanol/diethyl ether) prepared by reducing 14.55 g. (0.047 mole) of 4-[2-(3-benzoylphenyl)ethyl]morpholine oxime with 11.5 g. (0.50 mole) of sodium in 100 ml. of absolute ethanol.

Anal. Calcd. for $C_{19}H_{24}N_2O \cdot 2HCl$: C, 61.79; H, 7.10; Cl, 19.20.
Found: C, 61.88; H, 6.90; Cl, 19.16.

Example 16B. 4-{[3-(α -Aminobenzyl)phenyl]methyl}morpholine dihydrochloride monohydrate, m.p. 270—274° C. (8.3 g., from methanol/ether) prepared by reduction of 8.12 g. (0.027 mole) of 4-[3-benzylphenyl]methylmorpholine oxime with 6.45 g. (0.28 mole) of sodium in absolute ethanol.

Anal. Calcd. for $C_{18}H_{22}N_2O \cdot 2HCl \cdot H_2O$: C, 60.84; H, 6.81; Cl, 19.96.
Found: C, 60.68; H, 6.83; Cl, 20.27.

Example 16C. 4-{2-[3-(α -Aminobenzyl)phenyl]propyl}morpholine dihydrochloride m.p. 255—265° C. (9.5 g., from methanol/diethyl ether) prepared by reduction of 10.0 g. (0.03 mole) of 4-[2-(3-benzoylphenyl)propyl]morpholine oxime with 7.1 g. (0.31 mole) of sodium in 65 ml. of absolute ethanol.

Anal. Calcd. for $C_{20}H_{26}N_2O \cdot 2HCl$: C, 62.66; H, 7.36; Cl, 18.50.
Found: C, 61.78; H, 7.17; Cl, 18.01.

Example 17.

A solution of 13.0 g. (0.031 mole) of 2-cyclohexylmethyl-1-{2-[3-(α -hydroxy- α -methylbenzyl)phenyl]propyl}piperidine (described in Example 6) in 130 ml. of methanol and 3 ml. of concentrated sulfuric acid was stirred and refluxed for forty-five minutes, then cooled, diluted with 100 ml. of water, basified with 5 ml. of 35% sodium hydroxide and extracted with hexane. The combined hexane extracts, on washing with brine, drying and evaporation to dryness gave 14.2 g. of an oil which was chromatographed on 260 g. of alumina in 8:92 diethyl ether/hexane. There was thus obtained 9.8 g. of 2-cyclohexylmethyl-1-{2-[3-(1-phenyl-1-vinyl)phenyl]propyl}piperidine as an oil.

Anal. Calcd. for $C_{29}H_{35}N$: C, 86.72; H, 9.79; N, 3.49.
Found: C, 86.79; H, 9.76; N, 3.28.

Example 18.

4-Methoxyphenylacetic acid (41.5 g., 0.25 mole) was converted to the corresponding acid chloride with 47.7 g. (0.4 mole) of thionyl chloride in benzene using the procedure described above in Example 1. The acid chloride thus produced (36.8 g., 0.2 mole) was reacted with 24.1 g. (0.21 mole) of 2,6-dimethylpiperidine in ether in the presence of 24.2 g. (0.24 mole) of triethylamine using the procedure described above in Example 1. The resulting 2,6-dimethyl-1-[(4-methoxyphenyl)acetyl]piperidine

(38.8 g., 0.15 mole) was reduced with lithium aluminum hydride and the product isolated in the form of the hydrochloride salt to give 15.22 g. of 2,6-dimethyl-1-[2-(4-methoxyphenyl)ethyl]piperidine hydrochloride, m.p. 195—200° C.

5 The latter (1.0 g., 0.004 mole), in the form of the free base, was added in small portions to a stirred mixture of 1.21 g. (0.009 mole) of aluminum chloride and 1.28 g. (0.009 mole) of benzoyl chloride. The resulting viscous mixture was stirred for about twelve hours at ambient temperature and then mixed with ice, 2 ml. of concentrated hydrochloric acid and 2 ml. of water. The resulting mixture was extracted with chloroform, and the chloroform extracts washed with brine, dried and evaporated to dryness to give 2,6-dimethyl-1-[2-(3-benzoyl-4-methoxyphenyl)ethyl]piperidine as a yellow oil. 10

Example 19.

15 A mixture of 45 g. (0.13 mole) of 2,6-dimethyl-1-[2-(3-benzoyl-4-methoxyphenyl)ethyl]piperidine (described above in Example 18) and 34.9 g. (0.26 mole) of aluminum chloride in tetrachloroethane was heated and stirred at 50° C. for about twelve hours and then poured into a solution of 30 ml. of concentrated hydrochloric acid and 30 ml. of ice water. The mixture was basified with sodium carbonate, extracted four times with chloroform, and the chloroform extracts washed with saturated brine, dried and evaporated to dryness to give crude product which was once again heated for twelve hours at 50° C. with 30 g. of aluminum chloride and 30 ml. of tetrachloroethane. On working up as before, there was obtained 8 g. of crude material which was dissolved in chloroform. The organic solution was washed five times with 10% sodium carbonate, once with brine, then dried and taken to dryness. The residue was dissolved in acetone, and the solution was treated with ethereal hydrogen chloride to give solid material which was recrystallized from isopropanol. There was thus obtained 5.8 g. of 2,6-dimethyl-1-[2-(3-benzoyl-4-hydroxyphenyl)ethyl]piperidine hydrochloride, m.p. 217—219° C. 20 25

Anal. Calcd. for $C_{22}H_{27}NO_2 \cdot NO_2 \cdot HCl$: C, 70.67; H, 7.55; N, 3.75.
Found: C, 70.87; H, 7.58; N, 3.73.

Example 20.

30 A solution of 13.2 g. (0.03 mole) of 2-cyclohexylmethyl-1-[2-[3-(α -hydroxy-4-chlorobenzyl)phenyl]propyl]piperidine (described above in Example 5), 16 ml. of concentrated nitric acid and 32 ml. of 50% perchloric acid in 160 ml. of 1,2-dimethoxyethane was heated under reflux for one and a quarter hours, then cooled, diluted with 50 ml. of water, basified with 150 ml. of 10% sodium hydroxide and extracted with hexane. The hexane extracts were washed once with water, once with brine, dried and evaporated to dryness to give 12 g. of crude product which was chromatographed on 200 g. of alumina using 10:90 ether/hexane as eluent. The first 75 ml. of eluate was discarded and the next 600 ml. was taken to dryness to yield 9.2 g. of 2-cyclohexylmethyl-1-[2-[3-(4-chlorobenzoyl)phenyl]propyl]piperidine. 35 40

Anal. Calcd. for $C_{28}H_{36}ClNO$: C, 76.77; H, 8.28; Cl, 8.09.
Found: C, 76.85; H, 8.35; Cl, 8.27.

Examples 20A—20D.

45 Following a procedure similar to that described in Example 20, the following compounds of formula I were similarly prepared: 45

Example 20A. 2 - Cyclohexylmethyl - 1 - [2 - (3 - benzoylphenyl)ethyl]piperidine (yellow oil) prepared by oxidation of 14.0 g. (0.03 mole) of 2-cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxybenzyl)phenyl]ethyl}piperidine (described above in Example 1A) in 227 ml. of a solution prepared by dissolving 44.5 ml. of 72% perchloric acid, 20 ml. of water and 32 ml. of concentrated nitric acid in 320 ml. of 1,2-dimethoxyethane. There was thus obtained 8.74 g. of product. 50

Anal. Calcd. for $C_{27}H_{35}NO$: C, 83.24; H, 9.06; N, 3.60.
Found: C, 83.46; H, 9.26; N, 3.75.

Example 20B. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (3 - chlorobenzoyl)phenyl]propyl}piperidine (yellow oil) prepared by oxidation of 17.0 g. (0.039 mole) of 2-cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 3 - chlorobenzyl)phenyl]propyl}piper- 55

Example 24.

Reduction of α -(3-bromophenyl)propionaldehyde with sodium borohydride using the procedure described in Example 3 and reaction of the resulting 2-(3-bromophenyl)propanol with an excess of dihydropyran at ambient temperature in the presence of a few drops of concentrated hydrochloric acid affords 2-(3-bromophenyl)propane tetrahydropyranyl ether. Reaction of the latter in diethyl ether with *n*-butyl lithium followed by reaction of the resulting lithio derivative with benzonitrile using the procedure described in Example 7 affords 2-(3-benzoylphenyl)propanol which, on reaction with *p*-toluenesulfonic acid in the presence of pyridine, affords 2-(3-benzoylphenyl)propanol *p*-toluenesulfonate. Reaction of the latter with 1-cyclohexylpiperazine in DMF in the presence of anhydrous potassium carbonate affords 1-[2-(3-benzoylphenyl)propyl]-4-cyclohexylpiperazine.

BIOLOGICAL TEST RESULTS.

The N-{3-[R₁-(phenyl)-C(=X)]-phenyl-lower-alkyl}amines of formulae I and Ia of the invention have been tested in the carrageenin edema (CE) and adjuvant arthritis (AA) tests and found to have anti-inflammatory activity. Data so obtained, stated in terms of percent inhibition at a dose expressed in terms of millimoles (μ M)/kg., are given in TABLE A below. For comparative purposes, data obtained in the carrageenin edema test on the reference compound (designated "Ref."), 4-[(3-benzoylphenyl)methyl]morpholine, disclosed in French Patent 1,549,342, are also given. All data were obtained on oral administration.

TABLE A

Example	Dose	C.E.	A.A.
1	0.005	13	56**
	0.02	23	73**
	0.08	60**	91**
	0.324	73**	—
1A	0.004	0	—
	0.02	0	—
	0.08	51**	—
	0.324	62**	—
1B	0.004	0	—
	0.02	0	—
	0.08	13	—
	0.324	Toxic	—
1C	0.08	40*	—
	0.324	77**	—
1D	0.08	36*	—
	0.324	65**	—
3	0.005	0	0
	0.02	3	2
	0.08	35*	30
3A	0.004	0	—
	0.02	0	—
	0.08	34**	—
	0.324	75**	—
3B	0.08	19	—
	0.16	—	91**
	0.324	63**	—
3E	0.004	14	—
	0.02	34**	—

TABLE A (Continued)

Example	Dose	C.E.	A.A.
4	0.004	0	—
	0.02	1	—
	0.08	18	—
	0.324	72**	—
5	0.004	14	—
	0.005	—	64**
	0.02	41*	70**
	0.08	—	88**
5A	0.004	0	—
	0.02	0	—
	0.08	58**	—
	0.324	68**	—
6	0.004	14	—
	0.02	5	—
	0.08	28*	—
	0.324	55**	—
7	0.004	0	—
	0.02	22	—
	0.08	—	63**
7A	0.08	45**	—
	0.16	—	90**
	0.324	60**	—
7B	0.004	3	—
	0.005	—	61**
	0.02	38*	55*
	0.08	—	85**
7C	0.004	0	—
	0.02	10	—
	0.08	58**	—
	0.324	75**	—
7D	0.08	37**	—
	0.16	—	100**
	0.324	49**	—
7E	0.08	33*	92**
	0.324	58**	—
7F	0.08	33**	91**
	0.16	—	Toxic
	0.324	51**	—
7G	0.004	33**	—
	0.02	42**	—
	0.08	—	76**
7H(base)	0.004	29*	—
	0.02	44**	—
	0.08	—	81**
7H(HCl)	0.08	68**	—
	0.324	73**	—
7J	0.08	62**	—
	0.324	66**	—

TABLE A (Continued)

Example	Dose	C.E.	A.A.
8	0.004	2	—
	0.02	21	—
	0.08	33**	—
	0.324	68**	—
9	0.004	0	—
	0.02	0	—
	0.08	21	—
	0.324	47**	—
10	0.005	7	25
	0.02	26*	63*
	0.08	60**	91**
11	0.004	0	—
	0.02	15	—
	0.08	29*	—
	0.324	64**	—
	0.005	21	69**
	0.02	41**	81**
	0.08	51**	87**
	0.324	69**	—
	0.004	0	37**
	0.015	15	52**
13	0.06	37*	78**
	0.08	54**	—
	0.324	56**	—
	0.004	16	—
15	0.02	43**	92**
	0.08	—	91**
	0.004	16	—
15A	0.08	27	—
	0.324	29	—
16	0.004	16	—
	0.005	—	80**
	0.02	31*	89**
	0.08	—	108**
16A	0.08	27	—
	0.324	39*	—
16B	0.08	0	—
	0.324	36*	—
16C	0.08	49**	—
	0.324	84**	—
17	0.004	9	—
	0.02	16	—
	0.08	47**	—
	0.324	67**	—
19	0.02	5	—
	0.08	0	—
	0.16	—	1
	0.324	23*	—

TABLE A (Continued)

Example	Dose	C.E.	A.A.
20	0.004	16	—
	0.005	—	63**
	0.02	52**	90**
	0.08	—	Toxic
20A	0.004	9	—
	0.02	25	—
	0.08	46**	—
	0.324	70**	—
20B	0.004	14	—
	0.02	0	—
	0.08	22*	—
	0.324	65**	—
20C	0.004	17*	—
	0.02	15	—
	0.08	19*	—
	0.324	51**	—
20D	0.004	0	—
	0.005	—	35*
	0.02	36**	54*
	0.08	—	79**
21	0.08	32	—
	0.324	46**	—
22	0.08	29	—
	0.324	63**	—
Ref	0.08	0	—
	0.324	23*	—

*Statistically different from controls p. <.05

**Statistically different from controls p. <.01

Certain of the N-{3-[R₁-(phenyl)-C(=X)]-phenyl-lower-alkyl}amines of formula I of the invention have been tested for anti-viral activity against herpes simplex virus types 1 and 2 and have been found to have anti-viral activity. Data so-obtained, expressed in terms of the Minimum Inhibitory Concentration (mcg./ml.), are given in TABLE B below.


TABLE B

Example	MIC
1B	50 mcg./ml.
5	6 mcg./ml.
10	6 mcg./ml.
12,14	6 mcg./ml.

WHAT WE CLAIM IS:—


1. A compound having the Formula I (herein) where R₁ represents hydrogen or one or two, which may be the same or different, lower-alkyl, hydroxy, lower-alkoxy, trifluoromethyl, lower-alkylmercapto, lower-alkylsulfinyl, lower-alkylsulfonyl or halogen selected from fluorine, chlorine and bromine; R₂ represents hydrogen, or lower-alkoxy

or hydroxy in the 4-position relative to the $\text{CHR}_3\text{CH}_2\text{—N=B}$ group, or lower-alkyl in either of the 2-, 4-, 5- or 6-positions; R_3 represents hydrogen or lower-alkyl; the group $>\text{C=X}$ represents $>\text{C=O}$, $>\text{C}(\text{R}_3)\text{OH}$, $>\text{C}(\text{R}_3)\text{H}$, $>\text{C=CH}_2$, $>\text{C=NOH}$ or $>\text{CHN}(\text{R}_3)_2$ (where R_3 is only hydrogen or methyl in the last case); and N=B represents one of the groups



where R_3 represents hydrogen or lower-alkyl and is the same or different when occurring more than once, R_4 and R_5 each represent lower-alkyl; R_6 and R_7 each represent hydrogen, lower-alkyl, cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, 3-cyclohexylpropyl or benzyl; Z represents O, S or N—R_8 ; R_8 represents lower-alkyl or cyclohexyl; and n is the integer 1, 2 or 3.

2. A compound according to claim 1, where R_1 represents hydrogen, or one or two, which may be the same or different, lower-alkyl, lower-alkoxy or halogen; R_2 represents hydrogen or lower-alkoxy or hydroxy in the 4-position relative to the $\text{CHR}_3\text{CH}_2\text{—N=B}$ group; N=B represents one of the groups



where R_6 represents hydrogen, lower-alkyl, cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, or 3-cyclohexylpropyl; R_7 represents hydrogen; and Z represents oxygen and R_3 , R_4 and n have the meanings given in claim 1.

3. A compound according to claim 2, where R_1 represents hydrogen or one or two, which may be the same or different, lower-alkoxy or halogen; R_2 represents

- hydrogen; $>C=X$ represents $>C=O$, $>CHOH$, $>CH_2$, $>C=NOH$ or $>CHNFl_2$; and n represents the integer 1 or 2.
4. A compound having the Formula Ia (herein) where the group $>C=X$ represents $>C=O$ and R_3 represents lower-alkyl or where the group $>C=X$ represents $>CHNH_2$ and R_3 represents hydrogen.
5. 2,6-Dimethyl-1-[2-(3-benzoyl-4-methoxyphenyl)ethyl]piperidine.
6. 2,6-Dimethyl-1-[2-(3-benzoyl-4-hydroxyphenyl)ethyl]piperidine.
7. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 4 - methylbenzyl)phenyl] - propyl}piperidine.
8. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - α - methylbenzyl)phenyl] - propyl}piperidine.
9. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (3 - methylbenzoyl)phenyl]propyl}piperidine.
10. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (2 - methylbenzoyl)phenyl]propyl}piperidine.
11. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - methylbenzyl)phenyl]propyl}piperidine.
12. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (1 - phenyl - 1 - vinyl)phenyl]propyl}piperidine.
13. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxybenzyl)phenyl]propyl}piperidine.
14. 2,6-Dimethyl-1-[2-[3-(α -hydroxybenzyl)phenyl]propyl]piperidine.
15. 2-Cyclohexylmethyl-1-[2-(3-benzoylphenyl)propyl]piperidine.
16. 2-Cyclohexylmethyl-1-[2-(3-benzoylphenyl)propyl]piperidine.
17. 2,6-Dimethyl-1-[2-(3-benzoylphenyl)propyl]piperidine.
18. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 4 - methoxybenzyl)phenyl]propyl}piperidine.
19. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (4 - methoxybenzoyl)phenyl]propyl}piperidine.
20. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - hydroxy - 4 - chlorobenzyl)phenyl]propyl}piperidine.
21. 2 - Cyclohexylmethyl - 1 - [2 - (3 - benzoylphenyl)propyl]piperidine oxime.
22. 2 - Cyclohexylmethyl - 1 - {2 - [3 - (α - aminobenzyl)phenyl]propyl}piperidine.
23. N - [2 - (3 - Benzoylphenyl)ethyl] - N - (3 - dimethylaminopropyl)-amine.
24. 2 - (3 - Cyclohexylpropyl) - 1 - {2 - [3 - (α - hydroxybenzyl)phenyl]propyl}piperidine.
25. 2 - Cyclohexylmethyl - 1 - [2 - (3 - benzoylphenyl)propyl]pyrrolidine.
26. 2 - Cyclohexylmethyl - 1[2 - [3 - (4 - fluorobenzoyl)phenyl]propyl]piperidine.
27. 8 - [2 - (3 - Benzoylphenyl)propyl] - 1,4 - dioxo - 8 - azaspiro - [4,5]-decane.
28. 4-[2-(3-Benzoylphenyl)propyl]morpholine.
29. 4-[2-[3-(α -Aminobenzyl)phenyl]propyl]morpholine.
30. 4-[3-(α -Aminobenzyl)phenyl]methylmorpholine.
31. 4-[1-(3-Benzoylphenyl)ethyl]morpholine.
32. An acid-addition salt of a compound according to any one of the preceding claims.
33. A process for preparing a compound according to claim 1, or an acid-addition salt thereof which comprises:
- a) preparing a compound wherein $>C=X$ represents $>CR_3OH$ and R_3 is H by reducing with an alkali metal aluminum hydride a corresponding compound having the Formula V (herein) or preparing a compound wherein $>C=X$ represents $>C=O$ by oxidizing the $>C(H)OH$ group of the compound obtained or by ketalizing the $>C=O$ group of the compound of Formula V prior to the reduction step and then deketalizing after the reduction step;
- b) preparing a compound wherein $>C=X$ represents $>C=O$ and R_2 represents hydroxy or lower-alkoxy in the 4-position by reacting, in the presence of a Lewis acid, a compound having the Formula VI (herein) with a compound having the Formula VII where Hal represents halogen;
- c) preparing a compound wherein $>C=X$ represents $>C=O$ by reacting a compound of the Formula VIII with an amine of the formula $H-N=B$ in the presence of an acid-acceptor; or

d) preparing a compound in which $>C=X$ represents $>C(R_3)OH$ or $>C=O$ by reacting a compound of Formula IXa (herein) with a compound of Formula XX, XXI or XXII (herein) wherein a compound of Formula I wherein $>C=X$ is $>C(H)OH$ (from XX), $>C=O$ (from XXI), $>C(R)OH$ wherein R is lower-alkyl (from XXII) is respectively produced;

and, if desired, reducing a compound obtained wherein $>C=X$ is $>C=O$ to obtain the corresponding compound wherein $>C=X$ is $>C(H)OH$;

and, if desired, to obtain a compound wherein $>C=X$ is $>CR_3H$, reducing with hydrogen over a catalyst in the presence of perchloric acid, a compound obtained wherein $>C=X$ is $>CR_3OH$;

and, if desired, to obtain a compound wherein $>C=X$ is $>C=NOH$ reacting, with hydroxylamine, a compound obtained wherein $>C=X$ is $>C=O$;

and, if desired, to obtain a compound wherein $>C=X$ is $>CHN(R_3)_2$ reducing a compound obtained wherein $>C=X$ is $>C=NOH$ with sodium in a lower-alkanol containing from one to four carbon atoms to obtain the compound wherein both R_3 's in said radical are hydrogens, and, if desired, methylating the compound obtained using formaldehyde in the presence of formic acid to prepare corresponding compound wherein each of said, R_3 's is methyl;

and, if desired, to obtain a compound wherein $>C=X$ is $>C=CH_3$ dehydrating a compound obtained wherein $>C=X$ is $>C(CH_3)OH$;

and, if desired, converting a free base obtained to an acid-addition salt thereof.


34. A process for preparing a compound according to claim 4, or an acid-addition salt thereof, which comprises:

a) preparing a compound wherein $>C=X$ represents $>C=O$ and R_3 represents lower-alkyl by reacting a compound of the Formula XIII (herein) with morpholine; or


b) preparing a compound wherein $>C=X$ represents $>CHNH_2$ and R_3 is hydrogen by reducing with sodium in a lower-alkanol a compound having the Formula Ia wherein $>C=X$ is $>C=NOH$ and R_3 is hydrogen;

and, if desired, converting a free base obtained to an acid-addition salt thereof.

35. A compound according to claim 1, wherein $>C=X$ does not include $>CHN(CH_3)_2$, $N=B$ does not include



wherein n is 1 or 2, R_3 does not include cyclohexyl, R_2 is other than in the 4-position relative to the $CHR_3CH_2-N=B$ group, or R_3 and R_6 are other than meta to Z in



36. A process according to claim 33, in which a compound according to claim 35 is prepared and which does not include the ketalization of step a), the process c), the process d) or the optional methylation of claim 33.

37. A process for preparing a compound according to claim 1 or 4, or an acid-addition salt thereof substantially as herein described with reference to the Examples.

38. A process for preparing a compound according to claim 1, or an acid-addition salt thereof substantially as herein described with reference to the Examples, excluding Examples 1C, 1D, 3A, B, C, D and E, 7C, 7G, H and J, 9, 15A, B and C, 16A, B and C, 20B, C and D, and 21—24.

39. A compound according to claim 1 or 4 when prepared by the process according to any one of claims 33, 34 and 36—38.

40. A compound according to claim 1 or 4, or an acid-addition salt thereof, substantially as herein described with reference to the Examples.

41. A compound according to claim 1, or an acid-addition salt thereof, substantially as herein described with reference to the Examples, excluding Examples 1C, 1D, 3A, B, C, D and E, 7C, 7G, H and J, 9, 15A, B and C, 16A, B and C, 20B, C and D and 21—24.

42. A pharmaceutical composition which comprises a compound according to any one of claims 1 to 32, 39 and 40 and a pharmaceutical carrier.

LANGNER PARRY,
Chartered Patent Agents,
59—62 High Holborn,
London, WC1V 6EJ,
Agents for the Applicants.

Printed for Her Majesty's Stationery Office by the Courier Press, Leamington Spa, 1978.
Published by the Patent Office, 25 Southampton Buildings, London, WC2A 1AY, from
which copies may be obtained.